Searching for selectivity: the identification of novel modulators for targeting dopaminergic signaling

Speaker: 
Dr. David Sibley
Location: 
RHPH 164
Date / Time: 
Thursday, October 20, 2022 - 4:00pm
Host: 
Benita Sjogren
Abstract: 

Curriculum Vitae

 

David R. Sibley, PhD, FASPET, FAAAS 

Molecular Neuropharmacology Section

National Institute of Neurological Disorders & Stroke/NIH 
35 Convent Drive, Room 3A201, MSC-3723  •  Bethesda, MD 20892-3723 
Office: 301-496-9316  •  Fax: 301-480-3726  •  Email: sibleyd@ninds.nih.gov 
Homepage: https://research.ninds.nih.gov/researchers/faculty/david-r-sibley-phd
 

 

Education

 

1977: Bachelor of Science, San Diego State University, San Diego, California.  Major in Biology with Chemistry minor

 

1982: Doctor of Philosophy in Physiology and Pharmacology, University of California, San Diego, School of Medicine, La Jolla, California. Dissertation Title: Ligand Binding Properties of Pituitary D-2 Dopaminergic Receptors.  Supervisor:  Dr. Ian Creese

 

 

Appointments

 

1982-1985       Postdoctoral Fellow, Departments of Medicine and Biochemistry, Duke University Medical Center, Durham, North Carolina, Supervisor:  Dr. Robert J. Lefkowitz, Nobel Laureate in Chemistry 2012

 

1985-1987       Senior Research Associate, The Howard Hughes Medical Institute, Laboratory of Molecular Biology, Duke University Medical Center, Durham, North Carolina, Supervisor:  Dr. Robert J. Lefkowitz, Nobel Laureate in Chemistry 2012

 

1987-1992       Head, Molecular Pharmacology Unit, Experimental Therapeutics Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland

 

1992-present   Chief, Section on Molecular Neuropharmacology, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland

 

 

Professional Society Memberships

 

1980-present   Member, Society for Neuroscience

1987-present   Member, American Society for Biochemistry and Molecular Biology

1988-present   Fellow, American Society for Pharmacology and Experimental Therapeutics

                        2002-2003       Secretary/Treasurer, Neuropharmacology Division

                     2005-2007       Chair, Neuropharmacology Division

                     2005-2007       Member, Council of Division Chairs

                     2005-2008       Member, Program Committee

                     2006-2012       Chair, Julius Axelrod Award Committee

                     2008-2011       Member, Astellas Award Committee

                     2008-2011       Member, Investment Subcommittee

                     2008-2009       Chair, Finance Committee

                     2009-2010       Secretary/Treasurer, ASPET

                     2010-2016       Member, Board of Publications Trustees

                     2015-2018       ASPET President-Elect/Active/Past

                     2020                Elected Fellow of ASPET (FASPET)

1994-present   Fellow, International College of Neuropsychopharmacology

1997-present   Fellow, American College of Neuropsychopharmacology

                         2001-2003       Member, Ethics Committee

                         2003-2006       Member, Finance Committee

                        2004                Elected Fellow of ACNP

                        2005-2008       Member, Education and Training Committee

                         2007-2017       Scientific Website Editor

                        2007-2019       Member, Publications Committee

                        2008-2009       Member, History Task Force

                        2012-2013       Member, Program Committee

2000-present   Member, International Catecholamine Society

                         2006-2008      President

                         2008-2012      Councilor

2004-present   Fellow, American Association for the Advancement of Science (AAAS)

                        2021                Elected Fellow of AAAS

2009-present   Member, American Society for Experimental Neurotherapeutics

2016-present   Member, British Pharmacology Society

2019-present   Member, American Chemical Society

 

 

Honors and Awards

 

2021                Elected Fellow, American Association for the Advancement of Science (AAAS)

2020                Elected Fellow, American Society for Pharmacology and Experimental Therapeutics

2018                UCSD Department of Pharmacology, Outstanding Alumnus Award

2010                National Institutes of Health Special Act or Service Award

2007                National Institutes of Health Special Act or Service Award

2006                NINDS/NIH Technology Transfer Award

2004                Elected Fellow of the American College of Neuropsychopharmacology

2003                National Institutes of Health Special Act or Service Award

1997                Recipient, Quality Step Increase Performance Award - NIH

1995                Recipient, National Institutes of Health Director's Award

1992                Honorable Mention, Society for Neuroscience Young Investigator Award

1992                Recipient, National Institutes of Health Award of Merit

1982-1985       Awarded NRSA, NIH Postdoctoral Fellowship in Pharmacology

1980-1982       Awarded NIH Graduate Traineeship in Neuropsychobiology

1977-1979       Awarded NIH Graduate Traineeship in Pharmacology

1977                Graduated with High Honors and Distinction in Biology from SDSU                     

1975                Awarded NSF Summer Undergraduate Research Participation Grant

1974-1977       Deans List, San Diego State University

 

 

Editorial Positions

 

2010-2016       Editor-in-Chief, Pharmacological Reviews

2007-2017       Society Website Editor, American College of Neuropsychopharmacology

2007-2012       Member, Editorial Board, Current Molecular Pharmacology

2007                Editor-in-Chief, Handbook of Contemporary Neuropharmacology, John Wiley & Sons

2007-2011       Member, Editorial Board, The Dopamine Receptors Virtual Academy

2006                Editor, Drug Discovery Today: Therapeutic Strategies. Special issue on CNS disorders

2006-2012       Member, Editorial Board, Molecular Pharmacology

                        2008-2010       Mini-reviews Editor

2005-2009       Member, Editorial Board, Current Psychiatry Reviews

2004-2012       Member, Editorial Board, Journal of Pharmacology & Experimental Therapeutics

2004-2012       Member, Editorial Board, Current Neuropharmacology

2003-2012       Member, Editorial Board, Neuropsychopharmacology

2001-present   Executive Editor, Journal of Receptors and Signal Transduction

2000-2010       Executive Editor, Pharmacology & Therapeutics

2000-2008       Executive Editor, Neuropharmacology

1999-2017       Member, Editorial Board, Synapse

1997-2000       Associate Editor, Pharmacology & Therapeutics

1996-2001       Member, Editorial Board, Journal of Biological Chemistry,

1995-2017       Member, Editorial Board, Current Protocols in Neuroscience

1995-2005       Book Series Editor, Receptor Biochemistry & Methodology series (7 volumes), John Wiley & Sons

1994                Editor, Regulation of Cellular Signal Transduction Pathways by Desensitization and Amplification, John Wiley & Sons

1992-2008       Handling Editor, Journal of Neurochemistry

1989-2010       Field Editor: Molecular Neuropsychopharmacology, Psychopharmacology

 

 

Scientific Review/Advisory Board Memberships

 

2020-2021       Member, NINDS Stadtman Faculty Search Committee

2015-present   Member, NIH Stadtman Faculty Search Committee on Molecular Pharmacology,

                     Co-Chair, 2016-2017, 2020-2021

2013-2014       Chair, Tenure Track Search Committee, NIDA Intramural Research Program

2006-present   Member NINDS Title 42 Scientific Staff Evaluation Committee,

                        Chair 2017-present

2006-2009       Member, NINDS Animal Care and Use Committee

2005-2008       Chair, External Advisory Board, NIH Program Project Grant “Dopamine and AT1 Receptor Interaction in Genetic Hypertension”

2004-2016       NINDS Representative/Member, Fishers Lane Scientific Users Committee

2003-2016       Member, NIAAA Promotions and Tenure Committee

2001-2005       Member, Royalty Subcommittee, NIH Technology Transfer Policy Board

1998-2008       Member, Scientific Advisory Board, National Parkinson Foundation, Inc.

1997-2001       Member, NINDS Safety Committee

1997-2000       Member, Scientific Review Committee, NIH Intramural Sequencing Center

1994-1996       Member, Scientific Advisory Board, Spectra Biomedical, Inc.

1992-2013       Member, User's Committee, NINDS/NIMH DNA Sequencing Facility

1991-2005       Member, NINDS Technical Advisory Committee, Co-chair, 2001-2005

1991-1995       Member, Scientific Advisory Board, Tourette Syndrome Association, Inc.

 

 

 

 

 

Scientific Meeting Organization

 

2018    Chair, Symposium on “Recent advances in the development of subtype-selective and signaling-biased drugs for D2–like dopamine receptors:  towards improved therapeutics for neuropsychiatric disorders”, World Congress on Pharmacology (IUPHAR) Meeting

2017    Chair, Symposium on “Leveraging New Paradigms for GPCR Drug Discovery”, Experimental Biology Meeting, Chicago

2015    Member, Organizing Committee, “Dopamine, Oscillations and the Basal Ganglia-Thalamocortical Circuit: 40 Years of Research at NIH and Beyond”, Bethesda, Maryland

2012    Member, Organizing Committee, 10th International Catecholamine Symposium (2009-2012)

2009    Member, Board of Directors, Winter Conference on Brain Research (2005-2009)

2009    Chair, Panel on “New Aspects of Dopamine Receptor and Transporter Structure/Function Identified using Novel Proteomics Approaches”, Winter Conference on Brain Research

2008    Chair, ASPET Division of Neuropharmacology Postdoctoral Fellows Symposium, Experimental Biology Meeting

2005    Chair, Symposium on “Functional Selectivity and Agonist Trafficking”, Experimental Biology Meeting

2004    Co-chair, Session on “Novel Approaches to CNS Drug Discovery: Allosterism, Interfaces and Receptoromics,” American College of Neuropsychopharmacology Meeting

2003    Co-chair, Session on “Functional Selectivity of Receptor Signaling: Epiphenomena or New Opportunities for Drug Discovery?” American College of Neuropsychopharmacology Meeting

2003    Co-chair, Symposium on “Actions of Hallucinogens and Atypical Antipsychotic Drugs at     Serotonin Receptors,” Experimental Biology Meeting

2002    Co-chair, Symposium on “Dopamine Receptor Trafficking and Signal Transduction”, Dopamine ‘02 Meeting

2002    Member, International Advisory Board, Dopamine ‘02 - Satellite Meeting of the XIVth International Congress of Pharmacology (2001-2002)

2001    Chair, Session on “Regulation of G-Protein Receptor Function by Direct Protein-Protein Interactions”, American College of Neuropsychopharmacology Meeting

2001    Chair, Session on “Neurogenomics and Proteomics and Neuropsychiatric Disorders,” 7th National Parkinson Foundation International Symposium on Parkinson’s Disease Research

2000    Chair, Session on “Structural Insights into Dopamine Receptor Pharmacology, Activation and Regulation”, American College of Neuropsychopharmacology Meeting

1998    Chair, Session on "Catecholamine Receptors," Society for Neuroscience Meeting

1998    Co-chair, Symposium on Novel Dopamine Receptor Subtypes (D3/D4/D5) and their Ligands, XIIIth International Congress of Pharmacology, Munich, Germany

1998    Member, International Advisory Board, Dopamine '98 - Satellite Meeting of the XIIIth International Congress of Pharmacology    

1996    Chair, Session on "Is the D4 Dopamine Receptor a Target for Atypical Antipsychotic Drugs?" at 8th International Catecholamine Symposium

1996    Member, Executive Organizing Committee, 8th International Catecholamine Symposium

1994    Member, Organizing Committee, "Dopamine '94" - Satellite Meeting of the XIIth International Congress of Pharmacology

1994    Co-chair, Symposium on "Dopamine Receptors: Signal Transduction and Regulation Mechanisms," at Dopamine '94 International Conference

1994    Co-chair, Session on "Neuroleptics and Antipsychotics," XIXth CINP Congress

1993    Co-chair, Session on "Catecholamine Receptors," Society for Neuroscience Meeting

1992    Co-chair, Symposium on "Dopamine Receptors, G-Proteins and Second Messengers," at the 7th International Catecholamine Symposium

1992    Co-chair, Symposium on "Molecular Biology of Dopamine Receptors and Transporters, at Dopamine '92 - From Neurobiology to Neuropathology

1990    Co-chair, Symposium on "Receptor-Effector Gene Families: Function and             Evolution," National Institutes of Health Research Festival

 

Invited Presentations at Scientific Meetings

 

2022    Keynote Speaker, Mid-Atlantic Pharmacology Society Meeting, “Searching for selectivity: the identification of novel modulators for targeting the D2 dopamine receptor”, Philadelphia, Pennsylvania

2022    Keynote Speaker, 4th International PharmScience Research & Development, “Searching for selectivity: the identification of novel modulators for targeting dopaminergic signaling”, San Francisco, California

2018    51st Winter Conference on Brain Research, “GPCR functional selectivity: when bias is a good thing”, Whistler, British Columbia

2018    World Congress on Pharmacology (IUPHAR) Meeting, Identification of structural elements that regulate signaling bias in D2-like dopamine receptors, Kyoto, Japan

2017    50th Winter Conference on Brain Research, “The D2 Dopamine Receptor: from slice to behavior”, Big Sky, Montana

2016    Experimental Biology Meeting 2016, Moderator: Hear it from the Editors: Navigating the Course through Journal Submission and Publication, San Diego

2015    National Institutes of Health, Introduction, “Dopamine, Oscillations and the Basal Ganglia-Thalamocortical Circuit: 40 Years of Research at NIH and Beyond”, Bethesda, Maryland

2014    National Institutes of Health Research Festival, “Dopamine receptors – signaling through multiple pathways and relevance to the design of receptor-specific biased ligands”, Bethesda, Maryland

2014    GTC conference on GPCR Structure Function and Drug Discovery, "Identification of Functionally Selective Ligands for the D2 Dopamine Receptor", Boston, Massachusetts

2013    Keynote Speaker, Upstate New York Pharmacology Society Regional Chapter meeting of ASPET, "Using high throughput screening approaches to identify novel dopamine receptor modulators", Buffalo, New York

2013    Dopamine 2013 International Conference, “Identification of a novel dopaminergic ligand that is a biased agonist at the D2 dopamine receptor and an antagonist at the D3 receptor, Alghero, Italy

2012    10th International Catecholamine Symposium, “Sorting Nexin-25 Interacts with D1 and D2 Dopamine Receptors to Regulate Receptor Expression and Signaling,” Pacific Grove, California

2011    Annual Meeting of the European Association of Nuclear Medicine, “In vitro models to study receptor and transporter trafficking”, Birmingham, Great Britain

2009    Discussant, Symposium on D1/D2 interactions in the striatum: clinical, preclinical and mechanistic observations, American College of Neuropsychopharmacology meeting, Hollywood, Florida

2009    42nd Winter Conference on Brain Research, “Reciprocal Modulation of Function Between Dopamine Receptors and the Na+, K+-ATPase”, Copper Mountain, Colorado

2009    42nd Winter Conference on Brain Research, “Regulation of D1 Receptor Signaling by PKC and Ethanol”, Copper Mountain, Colorado,

2008    Experimental Biology 2008, “EthanolPotentiation of D1 Receptor Signaling: the role of PKC”, San Diego, California

2008    Experimental Biology 2008, Julius Axelrod Symposium, “Historical Perspectives”, San Diego, California

2006    39th Winter Conference on Brain Research, “Phosphorylation-Independent Regulation of D2 Dopamine Receptors”, Steamboat Springs, Colorado

2005    38th Winter Conference on Brain Research, “Getting a ‘GRIP’ on Dopamine Receptors”, Breckenridge, Colorado

2004    Wenner-Gren Foundation: Symposium on Receptor-Receptor Interactions Among Hepatahelical Membrane Receptors: from Structure to Function, “Dopamine receptor interactions with structural and scaffolding proteins,” Stockholm, Sweden

2003    Keynote Speaker, Symposium on Neuroscience and Molecular Genetics of Neuropsychiatric Disorders, “Current Application of Knock-Out Techniques: The Molecular Biology of Dopamine Receptors,” Royal College of Surgeons in Ireland, Dublin

2003    IBRO Meeting, Symposium on Neuropharmacology of Dopamine Receptors, “Characterization of D5 Receptor-Deficient Mice”, Prague, Czech Republic

2003    36th Winter Conference on Brain Research, Interactions of Dopamine Receptor Subtypes with Specific Structural and Scaffolding Proteins, Snowbird, Utah

2002    Dopamine 2002 - Satellite Meeting of the XIVth International Congress of Pharmacology, "Structural Insights into D1 Dopamine Receptor Phosphorylation and Desensitization", Portland, Oregon

2001    American College of Neuropsychopharmacology, “Identification and Characterization of Dopamine Receptor Subtype Interactions with Specific Structural and Scaffolding Proteins.” Waikoloa, Hawaii

2001    ASN/ISN World Congress of Nephrology, “Structural Insights into D1 Dopamine Receptor Phosphorylation and Desensitization,” San Francisco, California

2001    9th International Catecholamine Symposium, “Structural Insights into D1 Dopamine Receptor Phosphorylation and Desensitization”, Kyoto, Japan

2000    American College of Neuropsychopharmacology, “Structural Insights into D1 Dopamine Receptor Phosphorylation and Desensitization”, San Juan, Puerto Rico

1998    Dopamine '98 - Satellite Meeting of the XIII International Congress of Pharmacology, "Generation and Characterization of D5 Dopamine Receptor Knock-Out Mice," Strasbourg, France

1998    Symposium on Novel Dopamine Receptor Subtypes (D3/D4/D5) and their Ligands, XIIIth International Congress of Pharmacology, 1998, "Generation and Characterization of D5 Dopamine Receptor Knock-Out Mice," Munich, Germany

1997    Workshop on Neurobiology of Central Dopaminergic Neurotransmission, NIH Research Festival, "Molecular Neurobiology of Dopamine Receptors," Bethesda, Maryland

1996    8th International Catecholamine Symposium, "Regulation of the D1 Dopamine Receptor through cAMP-Mediated Pathways," Pacific Grove, California

1995    Gordon Research Conference on Catecholamines, "Generation of D1A dopamine receptor deficient mice by gene targeting," Barga, Italy

1994    Symposium on Serotonin in Neuroscience: Recent Breakthroughs in Research and New Potential Therapeutic Applications, "Cloning and Characterization of the 5-HT6 and 5-HT7 Receptor Subtypes," Philadelphia, Pennsylvania

1994    Dopamine '94 - Satellite Meeting of the XII International Congress of Pharmacology, "Differential Regulation of D2 Receptor Isoforms in Transfected Cells," Quebec City, Canada

1993    Society for Neuroscience Symposium on Unraveling the Complexity of the Serotonergic System:  Insights from Molecular Biology, "Cloning and Expression of a Novel Adenylyl Cyclase Stimulatory Receptor with High Affinity for Psychotropic Drugs," Washington, D.C.

1993    Joint Meeting of the Scientific Advisory Board and Medical Committee, Tourettte Syndrome Association, "Cloning of Dopamine Receptor Subtypes," Boston, Massachusetts

1992    Plenary Symposium on Dopamine: Molecules, Membranes, Movement and Mind, "Molecular Diversity of Dopamine Receptor Subtypes," National Institutes of Health Research Day, Bethesda, Maryland

1992    Dopamine '92 - From Neurobiology to Neuropathology, "Cloning, Expression and Characterization of the D1 Subfamily of Dopamine Receptor Subtypes," Sardinia, Italy

1992    7th International Catecholamine Symposium, "Dopamine Receptors: Cloning, Expression, and Regulation," Amsterdam, The Netherlands

1991    Second National Parkinson Foundation Conference on Parkinson Research, "Molecular Neurobiology of D1 Dopamine Receptors," Miami, Florida

1991    Society for Neuroscience Symposium on the Molecular Biology of the Dopamine System, "Molecular Neurobiology of D1 Dopamine Receptors," New Orleans, Louisiana

1991    Symposium on Dopamine Receptors: From Gene to Behavior, National Institutes of Health Research Day, "Molecular Biology and Cloning of Dopamine Receptor Subtypes," Bethesda, Maryland

1990    Dopamine '90 - Satellite Meeting of the XIth International Congress of Pharmacology, "Molecular Neurobiology of the D1 Dopamine Receptor," Como, Italy

1990    Symposium on Receptor-Effector Gene Families: Function and Evolution, National Institutes of Health Research Day, "Molecular Biology and Cloning of Dopamine Receptor Subtypes," Bethesda, Maryland

1990    United States-Israel Binational Science Foundation Workshop on Expression and Modulation of Receptors in Normal and Diseased Tissues, "Molecular Neurobiology and Regulation of Dopamine Receptors," Rehovot, Israel

1989    Dupont Symposium on Cloned Receptors: Pharmacology, Applications and Functional Significance,” Molecular Cloning and Characterization of a cDNA Encoding a Splice Variant of a Rat D2 Dopamine Receptor," Phoenix, Arizona

1987    15th Collegium Internationale Neuro-Psychopharmacologicum Congress: Symposium on Receptor Regulation and Receptor-Receptor Interaction:  Biochemical and Molecular Aspects, "Regulation of b-Adrenergic Receptor Function by Phosphorylation," San Juan, Puerto Rico

1986    New York Academy of Sciences Symposium on Receptor Regulation, "Molecular Mechanisms of b-Adrenergic Receptor Regulation," New York, New York

1986    American Society for Neurochemistry Symposium: Neurotransmitter Receptors:  Regulation and Function, "Regulation of b-Adrenergic Receptor Function by Phosphorylation," Montreal, Canada

1986    American Society for Neurochemistry Satellite Symposium: Molecular Mechanisms of Neuronal Responsivity, "Regulation of b-Adrenergic Receptor Coupled Adenylate Cyclase by Phosphorylation," Burlington, Vermont

1985    American Society for Cell Biology Summer Research Conference: Analytical Approaches for Receptor Biology, "Receptor Sequestration and Phosphorylation in Adrenergic Receptor Desensitization," Airlie, Virginia

 

 

Invited Seminar Presentations

 

2022    Department of Medicinal Chemistry and Molecular Pharmacology, Purdue University College of Pharmacy, “Searching for selectivity: the identification of novel modulators for targeting dopaminergic signaling”, West Lafayette, Indiana

2019    Department of Pharmacology, University of Texas Health Science Center, “Searching for selectivity: the identification of novel modulators for targeting dopaminergic signaling”, San Antonio, Texas

2018    Department of Pharmacology, University of California, San Diego School of Medicine, “Searching for selectivity: the identification of novel modulators that target dopaminergic signaling”, San Diego, California

2018    Department of Chemistry and Biochemistry, San Diego State University, “Searching for selectivity: the identification of novel modulators that target dopaminergic signaling”, San Diego, California

2014    Department of Pharmacology, University of Michigan Medical School, “Novel chemical probes for dopamine receptors”, Ann Arbor, Michigan

2013    Department of Pharmacology, Vanderbilt University School of Medicine, “HTS approaches for identifying novel orthosteric and allosteric dopamine receptor modulators,” Nashville, Tennessee

2012    Department of Pharmacology, Uniformed Services University of the Health Sciences, “HTS approaches for identifying novel dopamine receptor modulators,” Bethesda, Maryland

2011    Laboratory of Sensory Biology, National Institute of Dental and Craniofacial Research, “HTS approaches for identifying novel orthosteric and allosteric dopamine receptor modulators”, Bethesda, Maryland

2010    Boehringer Ingelheim Lecture, Department of Pharmacology, University of Montreal, “Novel mechanisms of D2 Dopamine Receptor Regulation and Modulation”, Montreal, Canada

2009    Israel Hanin Lecture, Department of Pharmacology, Loyola University Medical Center, “Novel Mechanisms of Dopamine Receptor Regulation,” Chicago, Illinois

2009    Department of Pharmacology, University of Texas Health Science Center, “Novel Mechanisms of Dopamine Receptor Regulation,” San Antonio, Texas

2009    Department of Pharmacology, Columbia University College of Physicians and Surgeons, “Novel Mechanisms of Dopamine Receptor Regulation,” New York, New York

2009    Department of Neuroscience, Chicago Medical School, Rosalind Franklin University of Medicine and Science, “Constitutive Regulation of Dopamine Receptor Signaling,” Chicago, Illinois

2008    Molecular Psychiatry Branch, NIDA, National Institutes of Health, “Constitutive Mechanisms of Dopamine Receptor Regulation,” Baltimore, MD

2008    Pulmonary/Critical Care Medicine Branch, NHLBI, National Institutes of Health, “Constitutive Mechanisms of Dopamine Receptor Regulation,” Bethesda, MD

2007    NIAAA Intramural Program, National Institutes of Health, “Constitutive Mechanisms of Dopamine Receptor Regulation,” Rockville, Maryland

2007    Georgetown University/VA Medical Center Grand Rounds, “Constitutive Mechanisms of Dopamine Receptor Regulation,” Washington, DC

2005    Department of Pharmacology, Drexel University College of Medicine, “Dopamine Receptor Proteomics and Regulation”, Philadelphia, Pennsylvania

2005    Department of Pharmacology, Creighton University Medical Center, Omaha, Nebraska, “Molecular Neurobiology and Regulation of Dopamine Receptors”

2004    Department of Pharmacology & Neuroscience, University of North Texas Health Science Center at Fort Worth, “Dopamine Receptor Proteomics & Regulation”, Fort Worth, Texas

2003    Department of Biochemistry, Case Western Reserve University School of Medicine, “Neurobiology and Regulation of Dopamine Receptors”, Cleveland, Ohio

2002    Neuroscience Discovery Division, Eli Lilly & Co., “Molecular Neurobiology and Regulation of D1-like Dopamine Receptors,” Indianapolis, Indiana

2002    NIAAA Intramural Program, National Institutes of Health, “Dopamine Receptor Proteomics and Regulation,” Rockville, Maryland

2001    Section of Neurobiology, Yale University School of Medicine, “Neurobiology and Regulation of D1-like Dopamine Receptors,” New Haven, Connecticut

1999    Pulmonary-Critical Care Medicine Branch, NIHLB, NIH, "Neurobiology and Regulation of D1-like Dopamine Receptors," Bethesda, Maryland

1999    Center for Molecular and Behavioral Neuroscience, Rutgers University, "Neurobiology and Regulation of D1-like Dopamine Receptors," Newark, New Jersey

1998    Addiction Research Center, National Institute on Drug Abuse, NIH, "Molecular Neurobiology of Dopamine Receptors," Baltimore, Maryland

1997    Department of Biochemistry and Molecular Biology, Merck Frosst Canada, Inc., "Molecular Regulation of Dopamine Receptors," Montreal, Canada

1995    CNS/Cardiovascular Research Division, Schering-Plough Research Institute, "Molecular Neurobiology of Dopamine and Serotonin Receptors," Kenilworth, New Jersey

1995    CNS Drug Discovery Division, Bristol-Myers Squibb Pharmaceutical Research Institute, "Molecular Neurobiology of Dopamine and Serotonin Receptors," Wallingford, Connecticut

1995    10th Annual Neuroscience Symposium, Central Virginia Chapter of the Society for Neuroscience, "Molecular Diversity of Dopamine and Serotonin Receptor Subtypes," Richmond, Virginia

1995    Pulmonary/Critical Care Medicine Branch, NHLBI, NIH, "Cloning and Characterization of Dopamine and Serotonin Receptor Subtypes," Bethesda, Maryland

1994    Department of Pharmacology, Texas Tech University Health Sciences Center, "Molecular Diversity of Dopamine Receptor Subtypes: Regulation and Signal Transduction Mechanisms," Lubbock, Texas

1994    Departments of Pharmacology and Molecular & Cellular Physiology, Stanford University, "Cloning and Characterization of Dopamine and Serotonin Receptor Subtypes," Palo Alto, California

1993    Department of Neuroscience, University of Health Sciences/The Chicago Medical School, "Cloning and Characterization of Dopamine and Serotonin Receptor Subtypes," North Chicago, Illinois

1992    Division of Cell Biology and Biophysics, School of Basic Life Sciences, University of Missouri-Kansas City, "Molecular Diversity of Dopamine Receptor Subtypes," Kansas City, Missouri

1992    Laboratory of Cellular Metabolism, NHLBI, NIH, "The Dopaminergic System: From Receptors to Neurophysiology - Part 1," Bethesda, Maryland,

1992    Laboratory of Molecular and Cellular Biology, NIDDK, NIH, "Molecular Actions of Dopamine," Bethesda, Maryland

1992    Clinical Neuroscience Branch, NINDS, National Institutes of Health, "Molecular Neurobiology of Dopamine Receptors," Bethesda, Maryland

1992    Department of Pharmacology, Medical College of Pennsylvania, "Molecular Neurobiology of Dopamine Receptors," Philadelphia, Pennsylvania

1992    Department of Pharmacology, Uniformed Services Health Sciences University "Molecular Neurobiology of Dopamine Receptors," Bethesda, Maryland

1991    Department of Neuroscience, Johns Hopkins University School of Medicine, "Molecular Neurobiology of Dopamine Receptors," Baltimore, Maryland

1991    Department of Pharmacology, Mount Sinai School of Medicine of the City University of New York, "Molecular Neurobiology of Dopamine Receptors," New York, New York

1991    Department of Pharmacology, University of Miami School of Medicine, "Molecular Neurobiology of Dopamine Receptors," Miami, Florida

1991    E.I. DuPont de Nemours & Co., "Molecular Neurobiology of Dopamine Receptors," Wilmington, Delaware

1991    Lafayette Clinic, Wayne State University, "Molecular Biology of Dopamine Receptor Subtypes," Detroit, Michigan

1991    Addiction Research Center, National Institute on Drug Abuse, ADAMHA, "Molecular Neurobiology of Dopamine Receptors," Baltimore, Maryland

1991    Neuroscience Group, Hoechst-Roussel Pharmaceuticals, "Molecular Biology of Dopamine Receptors," Somerville, New Jersey

1990    Department of Anatomy and Neurobiology, University of Vermont College of Medicine, "Molecular Biology of Dopamine Receptors," Burlington, Vermont

1990    Molecular Pathophysiology Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, "Molecular Cloning of Dopamine Receptor Subtypes," Bethesda, Maryland

1988    Neurogenetics Corporation, "Regulation of b-Adrenergic Receptor Function by Phosphorylation," Paramus, New Jersey

1987    Department of Pharmacology, University of California, Irvine, " b-Adrenergic Receptor-Coupled Adenylate Cyclase: Biochemical Mechanisms of Regulation," Irvine, California

1986    School of Pharmacy, University of Southern California, "Adenylate Cyclase-Coupled b-Adrenergic Receptors: Biochemical Mechanisms of Desensitization," Los Angeles, California,

1986    Department of Pharmacology, University of Tennessee, "Molecular Mechanisms of b-Adrenergic Receptor Desensitization," Memphis, Tennessee

1986    Department of Physiology, University of North Carolina, Chapel Hill, "Regulation of b-Adrenergic Receptor-Coupled Adenylate Cyclase," Chapel Hill, North Carolina

1986    Department of Pharmacology, Yale University, "Molecular Mechanisms of Hormone Receptor Desensitization," New Haven, Connecticut

1986    Department of Pharmacology, Temple University, "Mechanisms of Membrane-Receptor Regulation," Philadelphia, Pennsylvania

1986    Department of Pharmacology, Medical College of Pennsylvania, "Regulation of b-Adrenergic Receptor Function by Phosphorylation," Philadelphia, Pennsylvania

1986    Department of Pharmacology, University of Miami, "Molecular Mechanisms of b-Adrenergic Receptor Desensitization, Miami, Florida

1986    Department of Pharmacological Sciences, State University of New York, Stony Brook, "Receptor Sequestration and Phosphorylation in Adrenergic Receptor Desensitization," Stony Brook, New York

1986    Department of Pharmacology, Emory University, "b-Adrenergic Receptors: Biochemical Mechanisms of Regulation," Atlanta, Georgia

1986    Department of Pharmacology, Medical College of Virginia, "Regulation of b-Adrenergic Receptor Function by Phosphorylation," Richmond, Virginia

1986    Department of Biology, San Diego State University, "Regulation of b-Adrenergic Receptor Function by Phosphorylation," San Diego, California

1986    Department of Pharmacology, University of South Carolina, "Regulation of b-Adrenergic Receptor Function by Phosphorylation," Columbia, South Carolina

1982    Department of Medicine, University of California, San Diego, "Ligand Binding Properties of D-2 Dopaminergic Receptors," La Jolla, California

 

Patents

 

1.    Sibley, D.R., Monsma, F.J., Jr., McVittie, L.D., and Mahan, L.C., A cDNA Encoding the Long Isoform of the D2 Dopamine Receptor, U.S. Patent Numbers 5,128,254 and 5,552,289.

 

2.    Sibley, D.R., Monsma, F.J., Jr., Mahan, L.C., and McVittie, L.D., A cDNA encoding a Rat D1 Dopamine Receptor Linked to Adenylyl Cyclase Activation, U.S. Patent Number 5,610,282.

 

3.    Sibley, D.R., Monsma, F.J., Jr., and Shen, Y. and Hamblin, M., PCT-65 (5-HT7) Serotonin Receptor, U.S. Patent Number 5,914,236.

 

4.    Sibley, D.R. and Monsma, F.J., Jr., The St-B17 (5-HT6) Serotonin Receptor, U.S. Patent Number 6,844,190.

 

5.    Sibley, D.R., Monsma, F.J., Jr., and Hamblin, M.W., The St-B17 (5-HT6) Serotonin Receptor, European Patent Number 0668912. 

 

6.    Sibley, D.R., Monsma, F.J., Jr., and Shen, Y. and Hamblin, M.W., PCT-65 (5-HT7) Serotonin Receptor, European Patent Number 0666915.

 

7.    Sibley, D.R., Monsma, F.J., Jr., and Shen, Y. and Hamblin, M.W. The PCT-65 (5-HT7) Serotonin Receptor, Canadian Patent Number 2,147,838.

 

8.    Sibley, D.R., Monsma, F.J., Jr., and Hamblin, M.W., The St-B17 (5-HT6) Serotonin Receptor, Canadian Patent Number 2,147,839.

 

9.    Marugan, J.J., Xiao, X., Ferrer, M., Southall, N.T., Free, R.B., Sibley, D.R., 11-OXO-10,11-dihydrodibenzo[B,F][1,4]thiazepine S-oxide derivatives and their use as dopamine D2 receptor antagonists, U.S. Patent Number 9,550,742 and European Patent Number 3027612. 

 

10.  Sibley, D.R., Moritz, A., Free, R.B., Steiner, J., Southall, N., Ferrer, M., Hu, X., Weiner, W., Aubé, J., Frankowski, K., Selective D3 Dopamine Receptor Agonists and Methods of Their Use, U.S. Patent Application number 16/093,365, European Patent Number 3442955.

 

11.  Sibley, D.R., Luderman, K.D., Conroy, J.L., Free, R.B., Southall, N., Ferrer, M., Aubé, J., and Frankowski, K., Positive Allosteric Modulators of Dopamine 1 Receptor and Methods of Use Thereof, U.S. Patent Application 62/639,271, European Patent Application No. 19716018.7, pending.

 

12.  Sibley, D.R., Moritz, A.E., Free, R.B., Southall, N., Ferrer, M., Hu, X., and Frankowski, K., D3 dopamine receptor-selective negative allosteric modulators and methods of use thereof, U.S. Patent Application 63/228,660, pending.

 

13. Sibley, D.R., Free, R.B., Dulcey-Garcia, A., Nilson, A.N., Ferrer, M., Southall, N.T., and Marugan, D2 dopamine receptor-selective antagonists and methods of use thereof, U.S. Patent Application, pending.

 

 

PUBLICATIONS

 

Original Articles

 

1.         Donald, A., Sibley, D., Lyons, D.E., and Dahms, A.S., D-Galactonate Dehydrase, Purification and Properties, Journal of Biological Chemistry 254: 2132-2137, 1979.

 

2.         Sibley, D.R., and Creese, I., Guanine Nucleotides Regulate Anterior Pituitary Dopamine Receptors, European Journal of Pharmacology 55: 341-343, 1979.

 

3.         Creese, I., and Sibley, D.R., Radioligand Binding Studies: Evidence for Multiple Dopamine Receptors, Communications in Psychopharmacology 3: 385-395, 1979.

 

4.         Sibley, D.R. and Creese, I., Dopamine Receptor Binding in Bovine Intermediate Pituitary Membranes, Endocrinology 107: 1405-1409, 1980.

 

5.         Sibley, D.R., and Creese, I., Pseudo Non-Competitive Agonist Interactions with Dopamine Receptors, European Journal of Pharmacology 65: 131-133, 1980.

 

6.         Sibley, D.R., De Lean, A., and Creese, I., Anterior Pituitary Dopamine Receptors: Demonstration of Interconvertible High and Low Affinity States of the D-2 Dopamine Receptor, Journal of Biological Chemistry 257: 6351-6361, 1982.

 

7.         Sibley, D.R., Leff, S.E., and Creese, I., Interactions of Novel Dopaminergic Ligands with D-1 and D-2 Dopamine Receptors, Life Sciences 31: 635-645, 1982.

 

8.         Leff, S.E., Sibley, D.R., Hamblin, M.W. and Creese, I., Ascorbate Enables Reversible Dopaminergic 3H-Agonist Receptor Binding, Life Sciences 29: 2081-2090, 1982.

 

9.         Sibley, D.R., Weinberger, S.D., Segal, D.S., and Creese, I., Multiple Daily Amphetamine Administration Decreases both 3H-Agonist and 3H-Antagonist Dopamine Receptor Binding, Experientia 38: 1224-1225, 1982.

 

10.       Sibley, D.R., Mahan, L.C., and Creese, I., Dopamine Receptor Binding on Intact Cells: Absence of a High Affinity Agonist-Receptor Binding State, Molecular Pharmacology 23: 295-302, 1983.

 

11.       Sibley, D.R. and Creese, I., Regulation of Ligand Binding to Pituitary D-2 Dopaminergic Receptors: Effects of Divalent Cations and Functional Group Modification, Journal of Biological Chemistry 258: 4957-4965, 1983.

 

12.       Sibley, D.R., and Creese, I., Interactions of Ergot Alkaloids with Anterior Pituitary D-2 Dopamine Receptors, Molecular Pharmacology 23: 585-593, 1983.

           

13.       Sibley, D.R., Peters, J.R., Nambi, P., Caron, M.G., and Lefkowitz, R.J., Photoaffinity Labeling of Turkey Erythrocyte Beta-Adrenergic Receptors: Degradation of the Mr = 49,000 Protein Explains Apparent Heterogeneity, Biochemical and Biophysical Research Communications 119: 458-464, 1984.

 

14.       Nambi, P., Sibley, D.R., Stadel, J.M., Michel, T., Peters, J.R., and Lefkowitz, R.J., Cell-free Desensitization of Catecholamine-Sensitive Adenylate Cyclase: Agonist and cAMP Promoted Alterations in Turkey Erythrocyte b-Adrenergic Receptors, Journal of Biological Chemistry 259: 4629-4633, l984.

 

15.       Sibley D.R., Peters, J.R., Nambi, P., Caron, M.G., and Lefkowitz, R.J., Desensitization of Turkey Erythrocyte Adenylate Cyclase: b-Adrenergic Receptor Phosphorylation is Correlated with Attenuation of Adenylate Cyclase Activity, Journal of Biological Chemistry 259: 9742-9749, 1984.

 

16.       McDonald, W.M., Sibley, D.R., Kilpatrick, B.F., and Caron, M.G., Dopaminergic Inhibition of Adenylate Cyclase Correlates with High Affinity Agonist Binding to Anterior Pituitary D-2 Dopamine Receptors, Molecular and Cellular Endocrinology 36:  201-209, 1984.

 

17.       Strader, C.D., Sibley, D.R., and Lefkowitz, R.J., Association of Sequestered Beta-Adrenergic Receptors with the Plasma Membrane:  A Novel Mechanism for Receptor Down Regulation, Life Sciences 35: 1601-1610, 1984.

 

18.       Sibley, D.R., Nambi, P., Peters, J.R., and Lefkowitz, R.J., Phorbol Diesters Promote Beta-Adrenergic Receptor Phosphorylation and Adenylate Cyclase Desensitization in Duck Erythrocytes, Biochemical and Biophysical Research Communications 121: 973-979, 1984.

 

19.       Cerione, R.A., Sibley, D.R., Codina, J., Benovic, J.L., Winslow, J., Neer, E.J., Birnbaumer, L., Caron, M.G., and Lefkowitz, R.J., Reconstitution of a Hormone-Sensitive Adenylate Cyclase System:  The Pure b-Adrenergic Receptor and Guanine Nucleotide Regulatory Protein Confer Hormone Responsiveness on the Resolved Catalytic Unit, Journal of Biological Chemistry 259: 9979-9982, 1984.

 

20.       Nambi, P., Sibley, D.R., Caron, M.G., and Lefkowitz, R.J., Photoaffinity Labeling of b-Adrenergic Receptors in Mammalian Tissues, Biochemical Pharmacology 33: 3813-3822, 1984.

 

21.       Sibley, D.R., Strasser, R.H., Caron, M.G., and Lefkowitz, R.J., Homologous Desensitization of Adenylate Cyclase is Associated with Phosphorylation of the b-Adrenergic Receptor, Journal of Biological Chemistry 260: 3883-3886, 1985.

 

22.       Peters, J.R., Nambi, P., Sibley, D.R., and Lefkowitz, R.J., Enhanced Adenylate Cyclase Activity of Turkey Erythrocytes Following Treatment with b-Adrenergic Receptor Antagonists, European Journal of Pharmacology 107: 43-52, 1985. 

 

23.       Nambi, P., Peters, J.R., Sibley, D.R., and Lefkowitz, R.J., Desensitization of the Turkey Erythrocyte b-Adrenergic Receptor in a Cell-free System: Evidence that Multiple Protein Kinases Can Phosphorylate and Desensitize the Receptor, Journal of Biological Chemistry 260: 2165-2171, 1985. 

 

24.       Nambi, P., Sibley, D.R., and Lefkowitz, R.J., Sensitization of Frog Erythrocyte Adenylate Cyclase System by Tumor-Promoting Phorbol Diesters, Canadian Journal of Physiology and Pharmacology 63: 983-986, 1985.

 

25.       Nambi, P., Peters, J.R., Sibley, D.R., and Lefkowitz, J.R., Cell-Free Desensitization of the b-Adrenergic Receptor:  Evidence that Multiple Protein Kinases Can Phosphorylate and Desensitize the Receptor, Annals of the New York Academy of Sciences 463: 122-124, 1986.

 

26.       Sibley, D.R., Jeffs, R.A., Nambi, P., and Lefkowitz, R.J., Phorbol Diester Treatment Promotes Enhanced Adenylate Cyclase Activity in Frog Erythrocytes, Archives of Biochemistry and Biophysics 244: 373-381, 1986.

 

27.       Strasser, R.H., Sibley, D.R., and Lefkowitz, R.J., A Novel Catecholamine Activated cAMP Independent Pathway for b-Adrenergic Receptor Phosphorylation in Wild Type and Mutant S49 Lymphoma Cells: Mechanism of Homologous Desensitization of Adenylate Cyclase, Biochemistry 25: 1371-1377, 1986.

 

28.       Sibley, D.R., Strasser, R.H., Benovic, J.L., Daniel, K. and Lefkowitz, R.J., Phosphorylation/Dephosphorylation of the b-Adrenergic Receptor Regulates its Functional Coupling to Adenylate Cyclase and Subcellular Distribution, Proceedings of the National Academy of Sciences, USA 83: 9408-9412, 1986.

 

29.       Sibley, D.R. and Lefkowitz, R.J., Adenylate Cyclase Coupled b-Adrenergic Receptors:  Biochemical Mechanisms of Desensitization, Clinical Neuropharmacology 9: 3-5, 1986.

 

30.       Yoshimasa, T., Sibley, D.R., Lefkowitz, R.J. and Caron, M.G., Cross Talk Between Signaling Pathways Suggested by Phorbol Ester-Induced Adenylate Cyclase Phosphorylation, Nature 327: 67-70, 1987.

 

31.       Sibley, D.R., Strader, C.D., Daniel, K. and Lefkowitz, R.J., Phosphorylation of the b-Adrenergic Receptor in Intact Cells:  Relationship to Heterologous and Homologous Mechanisms of Adenylate Cyclase Desensitization, Archives of Biochemistry and Biophysics 258: 24-32, 1987.

 

32.       Yang, S.D., Fong, Y.L., Benovic, J.L., Sibley, D.R., Caron, M.G., and Lefkowitz, R.J., Dephosphorylation of the b-Adrenergic Receptor and Rhodopsin by Latent Phosphatase-2, Journal of Biological Chemistry 263: 8856-8858, l988.

 

33.       Munemura, M., Agui, T., and Sibley, D.R., Chronic Estrogen Treatment Promotes a Functional Uncoupling of the D2 Dopamine Receptor in Rat Anterior Pituitary Gland, Endocrinology 124: 346-355, 1989.

 

34.       Monsma, F.J., Jr., and Sibley, D.R., Direct Demonstration of D1Dopamine Receptors in Bovine Parathyroid Gland Membranes Using the D1Selective Antagonist [125I]-SCH 23982, Synapse 3: 193-199 1989.

 

35.       Monsma, F.J., Jr., Brassard, D.L., and Sibley, D.R., Identification and Characterization of D1 and D2 Dopamine Receptors in Cultured Neuroblastoma and Retinoblastoma Clonal Cell Lines, Brain Research 492: 314-324, 1989.

 

36.       Monsma, F.J., Jr., Barton, A.C., Kang, H.C., Brassard, D.L., Haugland, R.P., and Sibley, D.R., Characterization of Novel Fluorescent Ligands with High Affinity for D1 and D2   Dopaminergic Receptors, Journal of Neurochemistry 52: 1641-1644, 1989.

 

37.       McVittie, L.D., and Sibley, D.R., Solubilization of Phencyclidine Receptors from Rat Cerebral Cortex in an Active Ligand Binding State, Life Sciences 44: 1793-1802, 1989.

 

38.       Ariano, M.A., Monsma, F.J., Jr., Barton, A.C., Kang, H.C., Haugland, R.P., and Sibley, D.R., Direct Visualization and Cellular Localization of D1 and D2 Dopamine Receptors in Rat Forebrain by use of Fluorescent Ligands, Proceedings of the National Academy of Sciences (USA) 86: 8570-8574, 1989.

 

39.       Monsma, F.J., Jr., McVittie, L.D., Gerfen, C.R., Mahan, L.C., and Sibley, D.R., Multiple D2 Dopamine Receptors Produced by Alternative RNA Splicing, Nature 342: 926-929, 1989.

 

40.       Monsma, F.J., Jr., Barton, A.C., and Sibley, D.R., Expression of Functional D2 Dopamine Receptors Following Differentiation of Y-79 Human Retinoblastoma Cells, Journal of Neurochemistry 54: 1200-1207, 1990.

 

41.       Mahan, L.C., Burch, R.M., Monsma, F.J., Jr., and Sibley, D.R., Expression of Striatal D1 Dopamine Receptors Coupled to Inositolphosphate Production and Ca2+ Mobilization in Xenopus Oocytes, Proceedings of the National Academy of Sciences (USA) 87: 2196-2200, 1990.

 

42.       Monsma, F.J., Jr., Mahan, L.C., McVittie, L.D., Gerfen, C.R., and Sibley, D.R., Molecular Cloning and Expression of a D1 Dopamine Receptor Linked to Adenylyl Cyclase Activation, Proceedings of the National Academy of Sciences (USA) 87: 6723-6727, 1990.

 

43.       Barton, A.C., and Sibley, D.R., Agonist-Induced Desensitization of D1 Dopamine Receptors Linked to Adenylyl Cyclase Activity in Cultured NS20Y Neuroblastoma Cells, Molecular Pharmacology 38: 531-541, 1990.

 

44.       Gerfen, C.R., Engber, T.M., Susel, Z., Chase, T.N., Mahan, L.C., Monsma, F.J., Jr., and Sibley, D.R., Specific Expression of D1 and D2 Dopamine Receptors Mediates Differential Regulation of Striatonigral and Striatopallidal Pathways, Science 250: 1429-1432, 1991.

 

45.       McVittie, L.D., Ariano, M.A., and Sibley, D.R., Characterization of Anti-Peptide Antibodies for the Localization of D2 Dopamine Receptor in Rat Striatum, Proceedings of the National Academy of Sciences (USA) 88: 1441-1445, 1991.

 

46.       Kanterman, R.Y., Mahan, L.C., Briley, E.M., Monsma, F.J., Jr., Sibley, D.R., Axelrod, J., and Felder, C.C., Transfected D2 Dopamine Receptors Mediate the Potentiation of Arachidonic Acid Release in Chinese Hamster Ovary Cells, Molecular Pharmacology 39: 364-369, 1991.

 

47.       Barton, A.C., Kang, H.C., Rinaudo, M.S., Monsma, F.J., Jr., Stewart-Fram, R.M., Macinko, J.A., Jr., Haugland, R.P., Ariano, M.A., and Sibley, D.R., Multiple Fluorescent Ligands for Dopamine Receptors I: Pharmacological Characterization and Receptor Selectivity, Brain Research 547: 199-207, 1991.

 

48.       Ariano, M.A., Kang, H.C., Haugland, R.P., and Sibley, D.R., Multiple Fluorescent Ligands for Dopamine Receptors II:  Visualization in Neural Tissues, Brain Research 547: 208-222, 1991.

 

49.       Xu, S., Hatada, Y., Black, L.E., Creese, I., and Sibley, D.R., N-(p-isothiocyanatophenethyl)spiperone, a Selective and Irreversible Antagonist of D2 Dopamine Receptors in Brain, Journal of Pharmacology and Experimental Therapeutics 257: 608-615, 1991.

 

50.       Barton, A.C., Black, L.E., and Sibley, D.R., Agonist-Induced Desensitization of D2 Dopamine Receptors in Human Y-79 Retinoblastoma Cells, Molecular Pharmacology 39: 650-658, 1991.

 

51.       Mahan, L.C., McVittie, L.D., Smyk-Randall, E.M., Nakata, H., Monsma, F.J., Jr., Gerfen, C.R., and Sibley, D.R., Cloning and Expression of an A1 Adenosine Receptor from Rat Brain, Molecular Pharmacology 40: 1-7, 1991.

 

52.       Xu, S., Monsma, F.J., Jr., Sibley, D.R., and Creese, I., Regulation of D1 and D2 Dopamine Receptor mRNA During Ontogenesis, Lesions and Chronic Antagonist Treatment, Life Sciences 50: 383-396, 1992.

 

53.       Minowa, M.T., Minowa, T., Monsma, F.J., Jr., Sibley, D.R., and Mouradian, M.M., Characterization of the 5' Flanking Region of the Human D1A Dopamine Receptor Gene, Proceedings of the National Academy of Sciences (USA) 89: 3045-3049, 1992.

 

54.       Creese, I., Sibley, D.R., and Xu, S.X., Expression of Rat Striatal D1 and D2 Dopamine Receptor mRNAs: Ontogenetic and Pharmacological Studies, Neurochemistry International 20: S45-S48, 1992.

 

55.       Sibley, D.R., Monsma, F.J., Jr., McVittie, L.D., Gerfen, C.R., Burch, R.M., and Mahan, L.C., Molecular Neurobiology of Dopamine Receptor Subtypes, Neurochemistry International 20: S17-S22, 1992.

 

56.       Ariano, M.A., Stromski, C.J., Smyk-Randall, E.M., and Sibley, D.R., D2 Dopamine Receptor Localization on Striatonigral Neurons, Neuroscience Letters 144: 215-220, 1992.

 

57.       Yamaguchi, I., Jose, P.A., Mouradian, M.M., Canessa, L.M., Monsma, F.J., Jr., Sibley, D.R., Takeyasu, K., and Felder, R.A., Expression of the Dopamine D1A Receptor Gene in Proximal Tubule of Rat Kidneys, American Journal of Physiology 264 (33 No. 2 part 2): F280-F285, 1993.

 

58.       Felder, R.A., Kinoshita, S., Ohbu, K., Mouradian, M.M., Sibley, D.R., Monsma, F.J., Jr., Canessa, L.M., Lau, Y.S., Carey, R.M., and Jose, P.A., Organ Specificity of the Dopamine-1 Receptor/Adenylyl Cyclase Coupling Defect in the Spontaneously Hypertensive Rat, American Journal of Physiology 264 (33 No. 4 part 2): R726-R732, 1993.

 

59.       Monsma, F. J., Jr., Shen, Y. Ward, R.P., Hamblin, M.W., and Sibley, D.R., Cloning and Expression of a Novel Serotonin Receptor with High Affinity for Tricyclic Psychotropic Drugs, Molecular Pharmacology 43: 320-327, 1993.

 

60.       Ariano, M.J., Fisher, R.S., Manos, P., Smyk-Randall, E., Sibley, D.R., and Levine, M.S., D2 Dopamine Receptor Distribution in the Rodent CNS using Anti-peptide Antisera, Brain Research 609: 71-80, 1993.

 

61.       Wagner, H.-J., Luo, B.-G., Ariano, M.A., Sibley, D.R., and Stell, W.K., Localization of D2 Dopamine Receptors in Vertebrate Retinae with Anti-Peptide Antibodies, Journal of Comparative Neurology 331: 469-481, 1993.

 

62.       Chronwall, B.M., Dickerson, D.S., Sibley, D.R., and Gary, K.A., Plasticity and Ontogeny of Melanotrope D2A Dopamine Receptor mRNA and Isoform Protein Expression, Annals of the New York Academy of Sciences 680: 478-480, 1993.

 

63.       Shen, Y., Monsma, F.J., Jr., Metcalf, M.A., Jose, P.A., Hamblin, M.W., and Sibley, D.R., Molecular Cloning and Expression of a 5-HT7 Serotonin Receptor Subtype, Journal of Biological Chemistry 268: 18200-18204, 1993.

 

64.       David, C., Fishburn, C.S., Monsma, F.J., Jr., Sibley, D.R., and Fuchs, S., Synthesis and Processing of D2 Dopamine Receptors, Biochemistry 32: 8129-8183, 1993.

 

65.       Castellano, M.A., Xin, L.L., Monsma, F.J., Jr., Sibley, D.R., Kapatos, G., and Chiodo, L.A., Transfected D2 Short Dopamine Receptors Inhibit Voltage-Dependent Potassium Current in Neuroblastoma X Glioma (NG108-15) Cells, Molecular Pharmacology 44: 649-656, 1993.

 

66.       Chronwall, B.M., Dickerson, D.S., Pratt, B.S., Sibley, D.R., and Millington, W.R., Regulation of Heterogeneity in D2 Dopamine Receptor Gene Expression Among Individual Melanotrophs in the Rat Pituitary Intermediate Lobe, Molecular and Cellular Neurosciences 5: 35-45, 1994.

 

67.       Roth, B.L., Craigo, S.C., Choudhary, M.S., Monsma, F.J., Jr., Shen, Y., Meltzer, H.Y., and Sibley, D.R., Binding of Typical and Atypical Antipsychotic Agents to 5-Hydroxytryptamine6 (5-HT6) and 5-Hydroxytryptamine7 (5-HT7) Receptors, Journal of Pharmacology and Experimental Therapeutics 268: 1403-1410, 1994.

 

68.       Zhang, L.J., Lachowicz, J.E. and Sibley, D.R., The D2S and D2L Dopamine Receptor Isoforms are Differentially Regulated in Chinese Hamster Ovary Cells, Molecular Pharmacology 45: 878-889, 1994.

 

69.       Ariano, M.A. and Sibley, D.R., Dopamine Receptor Distribution in the Rat CNS:  Elucidation using Anti-Peptide Antisera Directed Against D1A and D3 Subtypes, Brain Research 649(1): 95-110, 1994.

 

70.       Fisher, R.S., Levine, M.S., Sibley, D.R., and Ariano, M.A., D2 Dopamine Receptor Protein Location:  Golgi Impregnation-Gold Toned and Ultrastructural Analysis of the Rat Neostriatum, Journal of Neuroscience Research 38: 551-564, 1994.

 

71.       Drago, J., Gerfen, C.R., Lachowicz, J.E., Steiner, H., Hollon, T.R., Love, P.E., Ooi, G.T., Grinberg, A., Lee, E., Hunag, S.P., Bartlett, P.F., Jose, P.A., Sibley, D.R., and Westphal, H., Altered Striatal Function in a Mutant Mouse Lacking D1A Dopamine Receptors, Proceedings of the National Academy of Sciences (USA) 91: 12564-12568, 1994.

 

72.       Black, L.E., Smyk-Randall, E.M., and Sibley, D.R., Cyclic AMP-Mediated Desensitization of D1 Dopamine Receptor-Coupled Adenylyl Cyclase in NS20Y Neuroblastoma Cells, Molecular and Cellular Neurosciences 5: 567-575, 1994.

 

73.       Lachowicz, J.E., Shen, Y., Monsma, F.J., Jr., and Sibley, D.R., Molecular Cloning of a Novel G-Protein Coupled Receptor Related to the Opiate Receptor Family, Journal of Neurochemistry 64: 34-40, 1995.

 

74.       Gonzalez, A.M. and Sibley, D.R., [3H]-7-OH-DPAT is Capable of Labeling the D2 as well as D3 Dopamine Receptors, European Journal of Pharmacology 272: R1-R3, 1995.

 

75.       Ward, R.P., Hamblin, M.W., Lachowicz, J.E., Hoffman, B.J., Sibley, D.R., and Dorsa, D.M., Localization of Serotonin Subtype 6 Receptor Messenger RNA in the Rat Brain by In Situ Hybridization Histochemistry, Neuroscience 64: 1105-1111, 1995.

 

76.       Gelernter, J., Rao, P.A., Pauls, D., Hamblin, M.W., Sibley, D.R., and Kidd, K.K., Assignment of the 5-HT7 Receptor Gene to Chromosome 10q and Exclusion of Genetic Linkage with Tourette's Syndrome, Genomics 26: 207-209, 1995.

 

77.       Kreiss, D.S., Bergstrom, D.A., Gonzalez, A.M., Huang, K.-X., Sibley, D.R., and Walters, J.R., Dopamine Receptor Agonist Potencies for Inhibition of Cell Firing Correlate with D3 Receptor Binding Affinities, European Journal of Pharmacology 277: 209-214, 1995.

 

78.       Glatt, C.E., Snowman, A.M., Sibley, D.R., and Snyder, S.H., Clozapine: Selective Labeling of Sites Resembling 5-HT6 Serotonin Receptors May Reflect Psychoactive Profile, Molecular Medicine 1: 398-406, 1995.

 

79.       Chase, T.N., Verhagen-Metman, L., Bravi, D., Roberts, J.W., Sibley, D.R., and Mouradian, M.M., Dopamine Receptor Subtype Selective Agonists in the Treatment of Parkinson's Disease, Clinical Neuropharmacology 18(Suppl. 1): S207-S215, 1995.

 

80.       O'Connell, D.P., Botkin, S.J., Ramos, S.I., Sibley, D.R., Ariano, M.J., Felder, R.A., and Carey, R.M. Localization of Dopamine D1A Receptor Proteins in Rat Kidney, American Journal of Physiology 268: F1185-F1197, 1995.

 

81.       Roth, B.L., Tandra, S., Burgess, L.H., Sibley, D.R., and Meltzer, H.Y., D4 Dopamine Receptor Binding Affinity does not Distinguish Typical and Atypical Antipsychotic Drugs, Psychopharmacology 120: 365-368, 1995.

 

82.       Max, S.I., Monsma, F.J., Jr., and Sibley, D.R., Agonist-Induced Desensitization of 5-HT6 Serotonin Receptor-Coupled Adenylyl Cyclase in Stably Transfected HEK-293 Cells, Journal of Serotonin Research 2: 101-116, 1995.

 

83.       Kohen, R., Metcalf, M.A., Khan, N., Druck, T., Huebner, K., Lachowicz, J.E., Meltzer, H.Y., Sibley, D.R., Roth, B.L., and Hamblin, M.W., Cloning, Characterization, and Chromosomal Location of a Human 5-HT6 Serotonin Receptor, Journal of Neurochemistry 66: 47-56, 1996.

 

84.       Accili, D., Fishburn, C.S., Drago, J., Steiner, H., Lachowicz, J.E., Park, B.-H., Gauda, E.B., Lee, E.J., Cool, M.H., Sibley, D.R., Gerfen, C.R., Westphal, H. and Fuchs, S., A Targeted Mutation of the D3 Dopamine Receptor Gene is Associated with Hyperactivity in Mice, Proceedings of the National Academy of Sciences (USA) 93: 1945-1949, 1996.

 

85.       Chronwall, B.M., Sands, S.A., Dickerson, D.S., Sibley, D.R., and Gary, K.A., Melanotrope Dopamine D2 Receptor Isoform Expression in the Developing Rat Pituitary, International Journal of Developmental Neuroscience 14(2): 77-86, 1996.

 

86.       Albrecht, F.E., Drago, J., Felder, R.A., Printz, M.P., Eisner, G.M., Robillard, J.E., Sibley, D.R., Westphal, H.J., and Jose, P.A., Role of the D1A Dopamine Receptor in the Pathogenesis of Genetic Hypertension, Journal of Clinical Investigation 97: 2283-2288, 1996.

 

87.       Levine, M.S., Altemus, K.L., Cepeda, C., Cromwell, H.C., Crawford, C. Ariano, M.A., Drago, J., Sibley, D.R., and Westphal, H., Modulatory Actions of Dopamine on N-Methyl-d-Aspartate Receptor-Mediated Responses are Altered in D1A Deficient Mice, Journal of Neuroscience 16: 5870-5882, 1996.

 

88.       Parikh, H., Liu, Li-Xin, Sibley, D.R., and Chiodo, L.A., D2S and D2L Dopamine Receptors Stably Transfected in NG108-15 Cells Increase Intracellular Calcium Via Different Signal Transduction Mechanisms, Neuroscience Net, Volume 1: Physiology Section, Article #10007 (http://www.neuroscience.com), 1996.

 

89.       Cravchik, A., Sibley, D.R., and Gejman, P.V., Functional Analysis of the Human D2 Dopamine Receptor Missense Variants, Journal of Biological Chemistry 271: 26013-26017, 1996.

 

90.       Liu, L.X., Monsma, F.J., Jr., Sibley, D.R., and Chiodo, L.A., D2L, D2S and D3 Dopamine Receptors Stably Transfected into NG108-15 Cells Couple to a Voltage-Dependent Potassium Current via Distinct G Proteins, Synapse 24: 156-164, 1996.

 

91.       Friedman, E., Jin, L.-Q., Cai, G.-P., Hollon, T.R., Drago, J., Sibley, D.R., and Wang, H.-Y., D1-like Dopaminergic Activation of Phosphoinositide Hydrolysis is Independent of D1A Dopamine Receptors: Evidence from D1A Knockout Mice, Molecular Pharmacology 51: 6-11, 1997.

 

92.       Ariano, M.A., Wang, J., Noblett, K.L., Larson, E.R., and Sibley, D.R., Cellular Distribution of the Rat D1B Receptor in CNS Using Anti-Receptor Antisera, Brain Research 746: 141-150, 1997.

 

93.       Ariano, M.A., Wang, J., Noblett, K.L., Larson, E.R., and Sibley, D.R., Cellular Distribution of the Rat D4 Dopamine Receptor Protein in the CNS using Anti-Receptor Antisera, Brain Research 752: 26-34, 1997.

 

94.       Schetz, J.A. and Sibley, D.R., Zinc Allosterically Modulates Antagonist Binding to Cloned D1 and D2 Dopamine Receptors, Journal of Neurochemistry 68: 1990-1997, 1997.

 

95.       Ariano, M.A., Larson, E.R., Noblett, K.L., Sibley, D.R., and Levine, M.S., Coexpression of Striatal Dopamine Receptor Subtypes and Excitatory Amino Acid Subunits, Synapse 26: 400-414, 1997.

 

96.       Lachowicz, J.E. and Sibley, D.R., Chimeric D2/D3 Dopamine Receptor Coupling to Adenylyl Cyclase, Biochemical and Biophysical Research Communications 237: 394-399, 1997.

 

97.       Ariano, M.A., Sortwell, C.E., Altemus, K.L., Sibley, D.R., and Levine, M.S., Agonist-induced Morphological Decrease in Cellular D1A Receptor Staining, Synapse 27: 313-321, 1997.

 

98.       El-Ghundi, M., George, S.R., Drago, J., Fletcher, P.A., Fan, T., Nguyen, T., Liu, C., Sibley, D.R., Westphal, H., and O'Dowd, B.F., Disruption of Dopamine D1 Receptor Gene Expression Attenuates Alcohol Seeking Behavior, European Journal of Pharmacology 353(2-3): 149-158, 1998.

 

99.       Ariano, M.A., Drago, J., Sibley, D.R., and Levine, M.S., Striatal Excitatory Amino Acid Receptor Subunit Expression in the D1A-Dopamine Receptor-Deficient Mouse, Developmental Neuroscience 20: 237-241, 1998.

 

100.     Liu, L.-X., Burgess, L.H., Gonzalez, A.M., Sibley, D.R. and Chiodo, L.A., D2S, D2L, D3 and D4 Dopamine Receptors Couple to a Voltage-Dependent Potassium Current in N18TG2 X Mesencephalon Hybrid Cells (MES-23.5) via Distinct G Proteins, Synapse 31: 108-118, 1999.

 

101.     Clifford, J.J., Tighe, O., Croke, D.T., Sibley, D.R., Drago, J., and Waddington, J.L., Topographical Evaluation of the Phenotype of Spontaneous Behaviour in Mice with Targeted Deletion of the D1A Dopamine Receptor: Paradoxical Elevation of Grooming Syntax, Neuropharmacology 37: 1595-1602, 1999.

 

102.     Cravchik, A., Sibley, D.R., and Gejman, P.V., Differences in Neuroleptic Activity at the Human D2 Dopamine Receptor Missense Variants, Pharmacogenetics 9: 17-23, 1999.

 

103.     Schetz, J.A., Chu, A., and Sibley, D.R., Zinc Modulates Antagonist Interactions with D2-like Dopamine Receptors Through Distinct Molecular Mechanisms, Journal of Pharmacology and Experimental Therapeutics 289: 956-964, 1999.

 

104.     Lawler, C.P., Prioleau, C., Lewis, M.M., Mak, C., Jiang, D., Schetz, J.A., Gonzalez, A.M., Sibley, D.R., and Mailman, R.B., The Molecular Pharmacology of the Novel Antipsychotic Aripiprazole (OPC-14597), Neuropsychopharmacology 20: 612-627, 1999.

 

105.     Cepeda, C., Li, Z., Cromwell, H.C., Altemus, K.L., Crawford, C.A., Nansen, E.A., Ariano, M.A., Sibley, D.R., Peacock, W.J., Mathern, G.G., and Levine, M.S., Electrophysiological and Morphological Analyses of Cortical Neurons Obtained from Children with Catastrophic Epilepsy: Dopamine Receptor Modulation of Glutaminergic Responses, Developmental Neuroscience 21: 223-235, 1999.

 

106.     Clifford, J.J., Tighe, O., Croke, D.T., Kinsella, A., Sibley, D.R., Drago, J. and Waddington, J.L., Conservation of Behavioral Topography to Dopamine D1-like Receptor Agonists in Mutant Mice Lacking the D1A Receptor Implicates a D1-like Receptor not Coupled to Adenylyl Cyclase, Neuroscience 93: 1483-1489, 1999.

 

107.     Jiang, D. and Sibley, D.R., Agonist-induced Desensitization of D1 Dopamine Receptors with Mutations of Cyclic AMP-dependent Protein Kinase Phosphorylation Sites: Attenuation of the Rate of Agonist-induced Desensitization, Molecular Pharmacology 56: 675-683, 1999.

 

108.     El-Ghundi, M., Fletcher, P.J., Drago, J., Sibley, D.R., O'Dowd, B.F., and George, S.R., Spatial Learning Deficit in Dopamine D1 Receptor Knockout Mice, European Journal of Pharmacology 383: 95-106, 1999.

 

109.     Schetz, J.A., Benjamin, P.S., and Sibley, D.R., Non-Conserved Residues in the Second Transmembrane-Spanning Domain of the D4 Dopamine Receptor are Molecular Determinants of D4-Selective Pharmacology, Molecular Pharmacology 57: 144-152, 2000.

 

110.     Schetz, J.A. and Sibley, D.R., Tandem Sulfur-Containing Amino Acids are Epicritical Determinants of D2 Dopamine Receptor Pharmacology, European Journal of Pharmacology 388: (2) R5-R7, 2000.

 

111.     Ventura, A.L.M and Sibley, D.R., Altered Regulation of the D1 Dopamine Receptor in Mutant Chinese Hamster Ovary Cells Deficient in Cyclic AMP-dependent Protein Kinase Activity, Journal of Pharmacology and Experimental Therapeutics 293: 426-434, 2000.

 

112.     Schetz, J.A. and Sibley, D.R., The binding site crevice of the D4 dopamine receptor is coupled to three unique sites of allosteric regulation, Journal of Pharmacology and Experimental Therapeutics 296: 359-363, 2001.

 

113.     Gardner, B., Liu, Z.F., Jiang, D. and Sibley, D.R., The Role of Phosphorylation/Dephosphorylation in Agonist-Induced Desensitization of D1 Dopamine Receptor Function: Evidence for a Novel Pathway for Receptor De-phosphorylation, Molecular Pharmacology 59: 310-321, 2001.

 

114.     Holmes, A., Hollon, T.R., Gleason, T.C., Liu, Z., Dreiling, J., Sibley, D.R., and Crawley, J.N., Dopamine D5 Receptor Null Mutant Mice Show Attenuated Behavioral Responses to a Dopamine Agonist, Behavioral Neuroscience 115: 1129–1144, 2001.

 

115.     Hunyady, B., Toth, Z., Palkovits, M., Mossik, G., Molnar, J., Feher, K., Zolyomi, A., Sibley, D.R. and Mezey, E., Susceptibility of Dopamine D5 Receptor Targeted Mice to Cysteamine, Journal of Physiology (Paris) 95 (1-6): 147-151, 2001.

 

116.     Ariano, M.A., Aronin, N., DiFiglia, M., Tagle, D.A., Sibley, D.R., Leavitt, B.R., Hayden, M.R. and Levine, M.S., Striatal Neurochemical Changes in Transgenic Models of Huntington’s Disease, Journal of Neuroscience Research 68: 716-29, 2002.

 

117.     Kim, O.J., Ariano, M.A., Lazzarini, R.A., Levine, M.S., and Sibley, D.R., Neurofilament-M Interacts with the D1 Dopamine Receptor to Regulate Cell Surface Expression and Desensitization, Journal of Neuroscience 22: 5920-5930, 2002.

 

118.     Hollon, T.R., Bek, M.J., Lachowicz, J.E., Ariano, M.A., Mezey, E., Ramachandran, R., Wersinger, S.R., Soares-da-Silva, P., Liu, Z.F., Grinberg, A., Drago, J., Young, W.S. III, Westphal, H., Jose, P.A. and Sibley, D.R., Mice Lacking D5 Dopamine Receptors Have Increased Sympathetic Tone and Are Hypertensive, Journal of Neuroscience 22: 10801-10810, 2002.

 

119.     Elliot, E.E., Sibley, D.R., and Katz, J.L., Locomotor and discriminative-stimulus effects of cocaine in dopamine D5 receptor knockout mice, Psychopharmacology 169: 161-168, 2003.

 

120.     Schetz, J.A., Kim, O.J., and Sibley, D.R., Pharmacological Characterization of Mammalian D1 and D2 Dopamine Receptors Expressed in Drosophila Schneider-2 Cells, Journal of Receptors and Signal Transduction 23: 99-109, 2003.

 

121.     Shapiro, D.A., Renock, S., Arington, E., Chiodo, L.A., Sibley, D.R., Roth, B.L., and Mailman, R., Aripiprazole, a Novel Atypical Antipsychotic with a Unique and Robust Pharmacology, Neuropsychopharmacology 28: 1400-1411, 2003.

 

122.     Kim, O.-J., Gardner, B.R., Williams, D.B., Marinec, P.S., Cabrera, D.M., Peters, J.D., Mak, C.C., Kim, K.-M. and Sibley, D.R., The Role of Phosphorylation in D1 Dopamine Receptor Desensitization: Evidence for a Novel Mechanism of Arrestin Association, Journal of Biological Chemistry 279: 7999-8010, 2004.

 

123.     Namkung, Y. and Sibley, D.R., Protein Kinase C Mediates Phosphorylation, Desensitization and Trafficking of the D2 Dopamine Receptor, Journal of Biological Chemistry 279: 49533-49541, 2004.

 

124.     Laplante, F., Sibley, D.R., and Quirion, R., Reduction in Acetylcholine Release in the Hippocampus of Dopamine D5 Receptor Deficient Mice, Neuropsychopharmacology 29: 1620-1627, 2004.

 

125.     Kudwa, A.E., Dominguez-Salazar, E., Cabrera, D.M., Sibley, D.R. and Rissman, E.F., Dopamine D5 Receptor Modulates Male and Female Sexual Behavior in Mice, Psychopharmacology 180: 206-214, 2005.

 

126.     O’Sullivan, G.J., Kinsella, A., Sibley, D.R., Tighe, O., Croke, D.T., and Waddington, J.L., Ethological Resolution of Behavioral Topography and D1-like vs. D2-like Agonist Responses in Congenic Dopamine D5 Receptor Mutants: Identification of D5:D2-like Interactions, Synapse 55: 201-211, 2005.

 

127.     Yang, Z., Asico, L.D., Yu, P., Wang, Z., Jones, J.E., Bai, R., Sibley, D.R., Felder, R.A., and Jose, P.A., D5 Dopamine Receptor Regulation of Phospholipase D, American Journal of Physiology 288(1): H55-61, 2005.

 

128.     Zeng, C., Yang, Z., Jones, J. Wang, X., Altea, J., Mangrum, A.J., Hopfer, U., Sibley, D.R., Eisner, G.M., Felder, R.A., and Jose, P.A., Interaction of AT1 and D5 Dopamine Receptors in Renal Proximal Tubule Cells, Hypertension 45: 804-810, 2005.

 

*129.   Rankin, M.L., Marinec, P.S., Cabrera, D.M., and Sibley, D.R., The D1 Dopamine Receptor is Constitutively Phosphorylated by G Protein Coupled Receptor Kinase 4: Evidence for a Novel Mechanism of Regulation, Molecular Pharmacology 69: 759-769, 2006.

 

*Accompanying commentary: Molecular Pharmacology 69: 673-676.

 

130.     Tomiyama, K., Makihara, Y., Yamamoto, H., O’Sullivan, G., Nally, R.E., Tighe, O., Kinsella, A., Fienberg, A.A., Grandy, D.K., Greengard, P., Low, M.J., Rubinstein, M., Sibley, D.R., Croke, D.T., Koshikawa, N., and Waddington, J.L., Disruption of Orofacial Movement Topographies in Congenic Mutants with Dopamine D5 but not D4 Receptor or DARPP-32 Transduction ‘Knockout’, European Neuropsychopharmacology, 16: 437-445, 2006.

 

131.     Yang, Z., Asico, L.D., Yu, P., Wang, Z., Jones, J.E., Escano, C.S., Quinn, M.T., Sibley, D.R., Romero, G.G., Felder, R.A., and Jose, P.A., D5 Dopamine Receptor Regulation of Reactive Oxygen Species Production, NADPH Oxidase, and Blood Pressure, American Journal of Physiology 290(1): R96-R104, 2006.

 

132.     Hernandez-Echeagaray, E., Cepeda, C., Ariano, M.A., Lobo, M.K., Sibley, D.R., and Levine, M.S., Dopamine Reduction of GABA Currents in Medium-sized Spiny Neurons is Principally Mediated by the D1 Receptor Subtype, Neurochemical Research, 32: 229-240, 2007.

 

133.     Wang, Z., Armando, I., Asico, L.D., Escano, C., Wang, X., Felder, R.A., Schnackenberg, C.G., Sibley, D.R., Robillard, J.E., Eisner, G.M., and Jose, P.A., The Elevated Blood Pressure of Human GRK4g A142V Transgenic Mice is not Associated with Increased ROS Production, American Journal of Physiology, 292(5): H2083-2092, 2007.

 

134.     Free, R.B., Hazelwood, L.A., Namkung, Y., Cabrera, D.M., Spalding, H.N., Rankin, M.L., and Sibley, D.R., D1 and D2 Dopamine Receptor Expression is Regulated by Direct Interaction with the Chaperone Protein Calnexin, Journal of Biological Chemistry, 282: 21285-21300, 2007.

 

135.     O’Sullivan, G., Dunleavy, M., Hakansson, K., Kinsella, A., Croke, D.T., Fienberg, A.A., Greengard, P., Sibley, D.R., Fisone, G., Henshall, D.C., and Waddington, J.L., Dopamine D1 vs D5 Receptor-Dependent Induction of Seizures Involves DARPP-32, ERK1/2 and GluR1-AMPA Signalling, Neuropharmacology, 54: 1051-1061, 2008.

 

136.     Li, H. Armando, I., Yu, P., Escano, C., Mueller, S., Asico, L., Pascua, A., Lu, Q., Villar, V., Jones, J., Periasamy, A., Creswell, K., Guillemette, G., Sibley, D.R., Felder, R., Jose, P.A., Dopamine D5 receptors mediate AT1 angiotensin receptor degradation via ubiquitin-proteosome pathway, Journal of Clinical Investigation, 118(6): 2180-2189, 2008.

 

137.     Kim, O.J., Ariano, M.A., Namkung, Y., Marinec, P., Kim, E., Han, J., and Sibley, D.R., D2 dopamine receptor expression and trafficking is regulated through direct interactions with ZIP, Journal of Neurochemistry, 106(1): 83-95, 2008.

 

138.     Rex, E.B., Rankin, M.L., Ariano, M.A., and Sibley, D.R., Ethanol Regulation of D1 Dopamine Receptor Signaling is Mediated by Protein Kinase C in an Isozyme-Specific Fashion, Neuropsychopharmacology, 32: 2900-2911, 2008.

 

139.     Seneca, N., Skinbjerb, M., Zoghbi, S.S., Liow, J.-S., Hong, J., Gladding, R.L., Hong, J., Kannan, P., Tuan, E., Sibley, D.R., Haldin, C., Pike, V.W., Innis, R.B., Kinetic brain analysis and whole-body imaging in monkey of [11C]-MNPA, a dopamine agonist radioligand, Synapse, 62: 700-709, 2008.

 

140.     Seneca, N., Zoghbi, S.S., Skinbjerb, M., Liow, J.-S., Hong, J., Sibley, D.R., Pike, V.W., Haldin, C., Innis, R.B., Occupancy of Brain D2/3 Receptors in Rat Brain by Endogenous Dopamine Measured with the Agonist Positron Emission Tomography Radioligand [11C]-MNPA, Synapse, 62: 756-763, 2008.

 

141.     Karlsson, R.M., Hefner, K.R., Sibley, D.R., and Holmes, A., Comparison of dopamine D1 and D5 receptor knockout mice for cocaine locomotor sensitization, Psychopharmacology, 100: 117-127, 2008.

 

142.     Argilli, E., Sibley, D.R., Malenka, R.C., England, R.C., England, P.M., and Bonci, A., Mechanism and time course of cocaine-induced LTP in the VTA, Journal of Neuroscience, 28: 9092-9100, 2008.

 

143.     Hazelwood, L.A., Free, B.F., Cabrera, D.M., Skinbjerb, M., and Sibley, D.R., Reciprocal modulation of function between the D1 and D2 dopamine receptors and the Na+, K+-ATPase, Journal of Biological Chemistry, 283: 36441-35453, 2008.

 

144.     Skinbjerb, M., Namkung, Y., Halldin, C., Innis, R.B., and Sibley, D.R., Pharmacological characterization of 2-methoxy-N-propylnorapomorphine’s (MNPA) interactions with D2 and D3 dopamine receptors, Synapse, 63: 462-475, 2009.

 

145.     Skinbjerb, M., Ariano, M.A., Thorsell, A., Heilig, M., Halldin, C., Innis, R.B., and Sibley, D.R., Arrestin3 mediates D2 Dopamine receptor internalization, Synapse, 63: 621-624, 2009.

 

146.     Sahu, A., Tyeryar, K.R., Vongtau, H.O., Sibley, D.R., and Undie, A.S., D5 dopamine receptors are required for dopaminergic activation of phospholipase C, Molecular Pharmacology, 75: 447-453, 2009.

 

147.     Namkung, Y., Dipace, C., Javitch, J.A., and Sibley, D.R., G protein-coupled receptor kinase-mediated phosphorylation mediates post-endocytic trafficking of the D2 dopamine receptor, Journal of Biological Chemistry, 284: 15038-15051, 2009.

 

148.     Namkung, Y., Dipace, C., Urizar, U., Javitch, J.A., and Sibley, D.R., G protein-coupled receptor kinase-2 constitutively regulates D2 receptor expression and signaling independently of receptor phosphorylation, Journal of Biological Chemistry, 284: 34103-34115, 2009.

 

149.     Skinbjerb, M., Seneca, N., Liow, J.-S., Hong, J., Weinschenker, D., Pike, V.W., Halldin, C., Sibley, D.R., and Innis, R.B., Dopamine-b-hydroxylase deficient mice have normal densities of D2 dopamine receptors in the high-affinity state based on in vivo PET imaging and in vitro radioligand binding data, Synapse, 64: 699-703, 2010.

 

150.     Skinberg, M., Liow, J.-S., Seneca, N., Hong, J., Lu, S., Thorsell, A., Heilig, M., Pike, V.W., Halldin, V., Sibley, D.R., and Innis, R.B., Dopamine D2 receptor internalization prolongs the decrease of radioligand binding after amphetamine: a PET study in a receptor internalization-defective mouse model, Neuroimage, 50: 1402-1407, 2010.

 

151.     Wang, X., Luo, Y., Escano, C.S., Yang, Z., Asico, L., Li, H., Jones, J.E., Armando, I., Lu, Q., Sibley, D.R., Eisner, G.M., Jose, P.A., Upregulation of renal sodium transporters in D5 dopamine receptor deficient mice, Hypertension, 55: 1431-1437, 2010.

 

152.     Rex, E., Rankin, M.L., Yang, Y., Lu, Q., Gerfen, C.R., and Sibley, D.R., Identification of RanBP9/10 as interacting partners for protein kinase Cs g/d and the D1 dopamine receptor: regulation of PKC-mediated receptor phosphorylation, Molecular Pharmacology, 78: 69-80, 2010.

 

153.     Rankin, M.L., and Sibley, D.R., Constitutive phosphorylation by protein kinase C regulates D1 dopamine receptor signaling, Journal of Neurochemistry, 115: 1655-1667, 2010.

 

154.     Kramer, P.F., Christensen, C.H., Hazelwood, L.A., Bobi, A., Bock, R., Sibley, D.R., Mateo, Y., Alvarez, V.A., Dopamine D2 receptor over-expression alters behavior and physiology in Drd2-GFP mice, Journal of Neuroscience, 31: 126-132, 2011.

 

155.     Asico, L., Zhang, X. Jiang, J. Cabrera, D. Escano, C. Sibley, D.R. Wang, X. Yang, Y., Mannon, R. Jones, J. Armando, I. Jose, P.A., Lack of renal dopamine D5 receptors promotes hypertension, Journal of the American Society of Nephrology, 22: 82-89, 2011.

 

156.     Reichart, D.L., Hinkle, R.T., Lefever, F.R., Dolan, E.T., Dietrich, J.A., Sibley, D.R., and Isfort, R.J., Activation of the dopamine D1 receptor increases skeletal muscle mass and force production, BMC Musculoskeletal Disorders, 12: 27-35, 2011.

 

157.     Banala, A.K., Levy, B.A., Khatri, S.S., Furman, C.A., Roof, R.A., Mishra, Y., Griffin, S.A., Sibley, D.R., Luedtke, R.R., Hauk-Newman, A., N-(3-Fluoro-4-(4-(2-methoxy or 2,3-dichlorophenyl) piperazine-1-yl)-butyl)-aryl carboxamides as Selective Dopamine D3 Receptor Ligands: Critical Role of the Carboxamide Linker for D3 Receptor Selectivity.  Journal of Medicinal Chemistry, 54: 3581-3594, 2011.

 

158.     Maison, S.F., Liu, X.-P., Eatock, R.A., Sibley, D.R., Grandy, D.K., and Liberman, M.C., Dopaminergic signaling in the cochlea: receptor expression patterns and deletion phenotypes, Journal of Neuroscience, 32: 344-355, 2012.

 

159.     Bergman, J., Roof, R.A., Furman, C.A., Conroy, J.L., Mello, N.K., Sibley, D.R., and Skolnick, P., Modification of cocaine self-administration by buspirone (Buspar®): potential involvement of D3 and D4 dopamine receptors, International Journal of Neuropsychopharmacology, 16: 445-458, 2013.

 

*160.   Chun, L.S., Free, R.B., Doyle, T.B., Huang, X.-P., Rankin, M.L., and Sibley, D.R., D1-D2 dopamine receptor synergy promotes calcium signaling via multiple mechanisms, Molecular Pharmacology, 84: 190-200, 2013.

 

            *F1000Prime Recommended: http://f1000.com/prime/718048681?bd=1&ui=21579

 

161.     Alexander, S.P. and CGTP Collaborators, Sibley, D.R., Dopamine Receptors, The concise guide to PHARMACOLOGY 2013/2014 overview, British Journal of Pharmacology, 170: 1449-1458, 2013.

 

162.     Xiao, J., Free, R.B., Barnaeva, E., Conroy, J.L., Doyle, T.B., Miller, B., Bryant-Genevier, M., Taylor, M.K., Hu. X., Dulcey, A. E., Southall, N., Ferrer, M., Titus, S., Zheng, Z., Sibley, D.R., and Marugan, J.J., Discovery, optimization, and characterization of novel D2 dopamine receptor selective antagonists, Journal of Medicinal Chemistry, 57: 3450-3463, 2014.

 

163.     Free, R.B., Chun, L.S., Moritz, A.E., Miller, B., Doyle, T.B., Conroy, J.L., Padron, Meade, J.A., Xiao, J., Hu, X., Dulcey, A.E., Han, Y., Duan, L., Titus, Bryant-Genevier, M., Barnaeva, E., Ferrer, M., Javitch, J.J., Beuming, T., Shi, L., Southall, N., Marugan, J.J., and Sibley, D.R., Discovery and characterization of a G protein-biased agonist that inhibits b-arrestin recruitment to the D2 dopamine receptor.  Molecular Pharmacology, 86:96-105, 2014. (Featured on journal cover).

 

164.     Ennis, R.C., Asico, L.D., Armanso, I., Yang, J., Feranil, J.B., Jurgens, J.A., Escano, C.S., Yu, P., Wang, X., Sibley, D.R., Jose, P.A., Villar, V.A.M., The D1-like receptors regulate the a1A adrenergic receptor in human renal proximal tubule cells and D1-like receptor knockout mice, American Journal of Physiology, 307(11): F1238-1248, 2014.

 

165.     Meade, J.A., Free, R.B., Miller, N.R., Doyle, T.B., Moritz, A.E., Conroy, J.L., Chun, L.S., Watts, V.J., and Sibley, D.R., (-)-Stepholidine is a potent pan-dopamine receptor antagonist of both G protein- and b-arrestin-mediated signaling, Psychopharmacology, 232: 917-930, 2015.

 

166.     Yang, S., Yang, Y., Yu, P., Yang, J., Villar, V.A.M., Sibley, D.R., Jose, P.A., Chunyu, Z., Dopamine D1 and D5 Receptors Differentially Regulate Oxidative Stress through Paraoxonase 2 in Kidney Cells, Free Radical Research, 49: 397-410, 2015.

 

167.     Frederick, A.L., Yano, H., Trifilieff, P., Vishwasrao, H.D., Biezonski, D., Meszaros, J., Sibley, D.R., Kellendonk, C., Sonntag, K.C., Graham, D.L., Colbran, R.J., Stanwood, G.D., and Javitch, J.A., Evidence against dopamine D1/D2 receptor heteromers, Molecular Psychiatry, 20(11): 1373-1385, 2015.

 

168.     Furman, C.A., Roof, R.A., Moritz, A., Miller, B.N., Doyle, T.B., Free, R.B., Banala, A.K., Paul, N.M., Kumar, V., Sibley, C.D., Newman, A.H., Sibley, D.R., Investigation of the binding and functional properties of extended-length D3 dopamine receptor-selective antagonists, European Neuropsychopharmacology, 25(9): 1448-1461, 2015.

 

169.     Dix, A.V., Conroy, J.L., Rosenker, K.M., Sibley, D.R., Appella, D.H., PNA-Based Multivalent Nanoscaffolds Activate the Dopamine D2 Receptor, ACS Medicinal Chemistry Letters, 13: 425-429, 2015.

 

170.     Conroy, J.L., Free, R.B., and Sibley, D.R., Identification of G protein-biased agonists that fail to recruit b-arrestin or promote internalization of the D1 dopamine receptor, ACS Chemical Neuroscience, 6: 681-692, 2015.

 

171.     Michino, M., Free, R.B., Sibley, D.R., and Shi, L., Structural basis for Na+ sensitivity in dopamine D2 and D3 receptors, Chemical Communications, 51: 8618-8621, 2015.

 

172.     Zou, M.-F., Keck, T.M., Kumar, V., Donthamsetti, P., Michino, M., Burzynski, C., Schweppe, Bonfazi, A., Free, R.B., Sibley, D.R., Janowsky, A., Shi, L., Javitch, J.A., and Newman, A.H., Novel analogs of (R)-5-(methylamino)-5,6,-dhydro-4H-imidazo[4,5,1-ij]quinolin-2(1H)-one (sumanirole) provide clues to dopamine D2/D3 receptor agonist selectivity, Journal of Medicinal Chemistry, 59: 2973-2988, 2016.

 

173.     Kumar, V., Moritz, A.E., Keck, T.M., Bonifazi, A., Ellenberger, M., Sibley, C.D., Free, B.F., Shi, L., Lane, J.R., Sibley, D.R.*, and Newman, A.H.*, Synthesis and pharmacological characterization of a novel series of trans-cyclopropylmethyl-linked 4-phenylpiperazine analogues that exhibit selectivity and allosteric pharmacology at the dopamine D3 receptor (D3R), Journal of Medicinal Chemistry, 60: 1478-1494, 2017. *co-corresponding authors         

174.     Carr, G.V., Maltese, F., Sibley, D.R., Weinberger, D.R., and Papaleo, F., The dopamine D5 receptor is critically involved in working memory, Frontiers in Pharmacology, 8: 666, 2017.

 

175.     Verma, R.K., Abramyan, A.M., Michino, M., Free, R.B., Sibley, D.R., Javitch, J.A., Lane, J.R., and Shi, L., The E2.65A mutation disrupts dynamic binding poses of SB269652 at the dopamine D2 and D3 receptors, PLOS Computational Biology, Jan 16;14(1): e1005948, 2018.

           

176.     Chun, L.S., Vekariya, R.H., Free, R.B., Li, Y., Lin, D.T., Liu, F., Namkung, Y., Laporte, S.A., Moritz, A.E., Aubé, J., Frankowski, K.J., and Sibley, D.R., Structure-activity investigation of a G protein biased agonist for the D2 dopamine receptor reveals molecular determinants for biased signaling, Frontiers in Synaptic Neuroscience, February 21; 10(2): 1-18, 2018.

 

177.     Luderman, K.D., Conroy, J.L., Free, R.B., Southall, N., Ferrer, M., Sanchez-Soto, M., Moritz, A.E., Willette, B.K.A., Fyfe, T.J., Jain, P., Titus, S., Hazelwood, L.A., Aubé, J., Lane, J.R., Frankowski, K.J., and Sibley, D.R., Identification of positive allosteric modulators of the D1 dopamine receptor that act at diverse binding sites., Molecular Pharmacology, 94: 1197-1209, 2018.

 

178.     Farino, Z.J., Morgenstern, T.J., Maffei, A., Quick, M., De Solis, A.J., Wiriyasermkul, P., Freyberg, R.J., Aslanoglou, D., Sorisio, D., Inbar, B.P., Free, R.B., Donthamsetti, P., Mosharov, E.V., Kellendonk., C., Schwartz, G.J., Sibley, D.R., Newman, A.H., Schmauss, C., Zeltser, L.M., Moore, H., Harris, P.E., Javitch, J.A., and Freyberg, Z., New roles for dopamine D2 and D3 receptors in pancreatic beta cell insulin secretion. Molecular Psychiatry, 25:2070-2085, 2019.

 

179.     Keck, T.M., Free, R.B., Day, M.M., Brown, S.L., Maddaluna, M.S., Fountain, G., Cooper, C., Fallon, B., Holmes, M., Stang, C.S., Burkhardt, R., Bonifazi, A., Ellenberger, M., Newman, A.H., Sibley, D.R., Wu, C., and Boateng, C.A., Dopamine D4 receptor-selective compounds reveal structure-activity relationships that engender agonist efficacy, Journal of Medicinal Chemistry, 62(7): 3722-3740, 2019.

 

180.     Bonaventura, J., Eldridge, M.A., Hu, F., Gomez, J.L., Sanchez-Soto, M., Abramyan, A.M., Lam, S., Boehm, M., Ruiz, C., Farrell, M., Shrestha, S.S., Telu, S., Zoghbi., S.S., Gladding, R.L., Moreno, A., Mustafa, I., Faress, G., Andersen, N., Lin, J.Y., Pike, V.W., Innis, R.B., Moaddel, R., Morris, P., Shi, L., Sibley, D.R., Mahler, S.V., Nabavi, S., Pomper, M.G., Bonci, A., Horti, A.G., Richmond, B.J., and Michaelides, M.,  High-potency ligands for DREADD imaging and activation in rodents and monkeys, Nature Communications 10: 4627, 2019.

 

181.     Bocarsly, M., Silva, D.D.S.E., Kolb, V., Luderman, K.D., Shashikiran, S., Rubinstein, M., Sibley, D.R., Dobbs, L.K., and Alvarez, V.A., A Mechanism Linking Two Known Vulnerability Factors for Alcohol Abuse: Heightened Alcohol Stimulation and Low Striatal Dopamine D2 Receptors, Cell Reports, 29 (5): 1147-1163, 2019.

 

182.     Sanchez-Soto, M., Verma, R.K., Willette, B.K.A., Gonye, E.C., Moore, A.M., Moritz, A.E., Yano, H., Free, R.B., Shi, L., and Sibley, D.R., A structural basis for how ligand binding site alterations can allosterically regulate GPCR signaling and engender functional selectivity, Science Signaling, Feb. 4;13(617), 2020.

 

183.     Castello, J., Cortés, M., Malave, L., Kottmann, A., Sibley, D.R., Friedman, E., and Rebholz, H., The dopamine D5 receptor contributes to activation of cholinergic interneurons during L-DOPA-induced dyskinesia, Scientific Reports, Feb 13;10(1):2542, 2020.

 

184.     Moritz, A.E., Free, R.B., Weiner, W.S., Akano, E., Gandhi, D., Abramyan, A., Keck, T.M., Ferrer, M., Hu, X., Southall, N., Steiner, J., Aubé, J., Shi, L., Frankowski, K.J., and Sibley, D.R., Discovery, Optimization and Characterization of ML417: A Novel and Highly Selective D3 Dopamine Receptor Agonist, Journal of Medicinal Chemistry, 63(10):5526-5567, 2020.

 

185.     Ågren, R., Zeberg, H., Stępniewski, T.M., Free, R.B., Reilly, S.W., Luedtke, R.R., Århem, P., Ciruela, F., Sibley, D.R., Mach, R.H., Salent, J., Nilsson, J., and Sahlholm, K., A ligand with two modes of interaction with the dopamine D2 receptor – an induced-fit mechanism of insurmountable antagonism, ACS Chemical Neuroscience, 11(19): 3130-3143, 2020.

 

186.     Moritz, A.E., Bonifazi, A., Guerrero, A., Kumar, V., Free, R.B., Lane, J.R., Verma, R.K., Shi, L., Newman, A.H., and Sibley, D.R., Evidence for a stereoselective mechanism for bitopic activity by extended-length antagonists of the D3 dopamine receptor, ACS Chemical Neuroscience, 11(20): 3309-3320, 2020.

 

187.     Luderman, K.D., Jain, P., Free, R.B., Conroy, J.L., Aubé, J., Sibley, D.R.*, and Frankowski, K.J.*, Development of pyrimidone D1 dopamine receptor positive allosteric modulators, Bioorganic and Medicinal Chemistry Letters, 31:127696, 2021 (*co-corresponding authors).

 

188.     Aslanoglou, D., Bertera, S., Sánchez-Soto, M., Free, R.B., Lee, J., Zong, W., Xue, X., Shrestha, S., Brissova, M., Logan, R.W., Yechoor, V.K., Sibley, D.R., Botinno, R., and Freyberg, Z., Dopamine regulates pancreatic glucagon and insulin secretion via adrenergic and dopaminergic receptors, Translational Psychiatry, 11(1):59, 2021.

 

189.     Bonaventura, Lam, S., Carlton, M., Boehm, Gomez, J.L., Solis-Castrejon, Sanchez-Soto, Morris, P.J., Fredriksson, I., Thomas, C.J., Sibley, D.R., Shaham, Y., Zarate, C.A., and Michaelides, M., Pharmacological and behavioral divergence of ketamine enantiomers: implications for abuse liability, Molecular Psychiatry, Apr 15, 2021.

 

190.     Lee, H., Jiang, X., Perwaiz, I., Yu, P., Wang, J., Wang, Y., Hutterman, M., Felder, R.A., Sibley, D.R., Polster, B.M., Rozyyev, S., Armando, I., Yang, Z., Qu, P., and Jose, P.A., Dopamine D5 receptor-mediated decreases in mitochondrial reactive oxygen species production are cAMP and autophagy dependent, Hypertension Research, 44: 628-641, 2021.

 

191.     Free, R.B., Cuoco, C.A., Prabhu, V.V., Willette, B.K.A., Day, M., Lane, J.R., Shi, L., Allen, J.E., and Sibley, D.R., Pharmacological characterization of the imipridone anti-cancer drug ONC201 reveals a negative allosteric mechanism of action at the D2 dopamine receptor, Molecular Pharmacology, 100 (4): 372-387, 2021. (Featured on journal cover)

 

192.     Bonaventura, J., Gomez, J.L., Carlton, M.L., Lam, S., Sanchez-Soto, M., Morris, P.J., Moaddel, R., Kang, H.J., Zanos, P., Gould, T.D., Thomas, C.J., Sibley, D.R., Zarate, C.J., and Michaelides, M., Target deconvolution studies of (2R,6R)-hydroxynorketamine: an elusive search, Molecular Psychiatry, in press, 2022.

 

193.     Aslanoglou, D., Bertera, S., Friggeri, L., Sánchez-Soto, M., Lee, J., Xue, X., Logan, R.W., Lane, J.R., Yechoor, V.K., Meiler, J., Free, R.B., Sibley, D.R., Botinno, R., and Freyberg, Z., Dual pancreatic adrenergic and dopaminergic signaling as a therapeutic mechanism of bromocriptine, iScience, July 19;25(8):104771, 2022.

 

194.     Free, R.B., Nilson, A.N., Boldizsar, N.M., Doyle, T.B., Rodriguiz, R.M., Machino, M., Lee, K.H., Bertz, J.W., Xu, J., Lim, H.D., Garcia, A.D., Mach, R.H., Woods, J.H, Lane, J.R., Shi, L., Marugan, J.J., Wetsel, W.C, and Sibley, D.R., Identification and Characterization of ML321: a novel and highly selective D2 dopamine receptor antagonist with efficacy in animal models that predict atypical antipsychotic activity, in submission, 2022.

 

195.     Akano, E.O., Novikov, N., Brazhnik, E., Moritz, A.E., McCoy, A.J., Free, R.B., Walters, J.R., and Sibley, D.R., Pharmacological actions of a novel and highly selective D3 dopamine receptor agonist, ML417, in a rodent model of Parkinson’s disease, in submission, 2022.

 

196.     Moritz, A.E., Madaras, N., Rankin, M.L., Inbody, L.R., and Sibley, D.R., Delineation of G protein-coupled receptor kinase phosphorylation sites within the D1 dopamine receptor and their function in regulating receptor signaling, in submission, 2022.

 

197.     Boateng, C.A., Nilson, A.N., Placide, R., Pham, M.L., Jakobs, F.M., Boldizsar, N.M., McIntosh, S., Stallings, L.S., Kelshikar, S., Shah, N., Panasis, D., Muccilli, A., Ladik, M., Maslonkaq, B., McBride, C., Sanchez, M.X., Acka, E., Bonifazi, A., Newman, A.H., Rais, R., Slusher, B.S., Free, R.B., Sibley, D.R., Stewart, K.D., Hemby, S.E., and Keck, T.M., Pharmacology and therapeutic potential of dopamine D4 receptor antagonists for cocaine use disorder, in submission, 2022. https://chemrxiv.org/engage/chemrxiv/article-details/62b8cfe61278ae6d38f17bd6.

 

 

Reviews and Book Chapters

 

1.         Creese, I. and Sibley, D.R., Regulation of Dopamine Receptors, In Psychopharmacology and Biochemistry of Neurotransmitter Receptors, (eds.) H.I. Yamamura, R. W. Olsen, E. Usdin, Raven Press, New York, pp. 387-410, 1980.

 

2.         Creese, I., Morrow, A.L., Leff, S.E., Sibley, D.R., and Hamblin, M.W., Dopamine Receptors in the Central Nervous System, International Review of Neurobiology Vol. 23, pp. 255-301, 1981.

 

3.         Creese, I. and Sibley, D.R., Receptor Adaptations to Centrally Acting Drugs, Annual Reviews in Pharmacology and Toxicology 21: 357-391, 1981.

 

4.         Creese, I., Sibley, D.R., Leff S., and Hamblin, M., Dopamine Receptors: Subtypes, Regulation, and Localization, Federation Proceedings 40: 147-152, 1981.

 

5.         Dahms, A.S., Sibley, D, Huisman, W., and Donald, A., D-Galactonate Dehydrase, Methods in Enzymology (Carbohydrate Metabolism, Part E) 90: 294-298, 1982.

 

6.         Creese, I. and Sibley, D.R., Comments on the Commentary by Dr. Seeman, Biochemical Pharmacology 31: 2568-2569, 1982.

 

7.         Sibley, D.R., Ligand Binding Properties of Pituitary D-2 Dopaminergic Receptors, Doctoral Dissertation, University of California, San Diego, 1982.

 

8.         Creese, I, Hamblin, M.W., Leff, S.E., and Sibley, D.R., CNS Dopamine Receptors, In Psychobiology of Schizophrenia, (ed.) H. Kaiya, Pergamon Press, pp. 139-153, 1982.

 

9.         Creese, I., Hamblin, M.W., Leff, S.A., and Sibley, D.R., CNS Dopamine Receptors, In Handbook of Psychopharmacology, Vol. 17, (eds.) L.L. Iversen, S.D. Iversen, S.H. Snyder, Plenum Press, New York, pp. 81-138, 1983.

 

10.       Creese, I., Sibley, D.R., Hamblin, M. W., and Leff, S.E., The Classification of Dopamine Receptors: Relationship to Radioligand Binding, Annual Reviews of Neuroscience 6: 43-71, 1983.

 

11.       Creese, I., Sibley, D.R., Hamblin, M.W., and Leff, S.E., Dopamine Receptors in the Central Nervous System, Molecular Pharmacology of Neurotransmitter Receptors, Advances in Biochemical Psychopharmacology, (eds.) T. Segawa and H. Yamamura, Raven Press, Vol. 36, pp. 125-134, 1983.

 

12.       Creese, I., Sibley, D.R., and Leff, S.E., Classification of Dopamine Receptors, In CNS Receptors - From Molecular Pharmacology to Behavior, Advances in Biochemical Pharmacology, (ed.) P. Mandel and F. V. DeFeudis, Raven Press, Vol. 37, pp. 255-266, 1983.

 

13.       Caron, M.G., Kilpatrick, B.F., and Sibley, D.R., Direct Measurement of Dopamine Receptors in the Anterior Pituitary Gland, Methods in Enzymology (Hormone Action, Part H. Neuroendocrine Peptides) 103: 577-590, 1983.

 

14.       Creese, I., Morrow, A.L., Leff, S.E., Hamblin, M.W., and Sibley, D.R., Radioligand Binding Studies of CNS Dopamine Receptors, In Proceedings of the 2nd Capo Boi Symposium of Neuroscience, (eds.) G. Biggio, P. Spano, and G. Gessa, Pergamon Press, pp. 1-50, 1983.

 

15.       Creese, I., Leff, S.E., Sibley, D.R., and Hamblin, M.W., Radioligand Binding Studies of Agonist Interactions with Dopamine Receptors, In Dopamine Receptor Agonists, Smith, Kline and French Symposia on Dopamine Receptors, (eds) G. Poste and S. T. Crooke Plenum Press, pp. 23-64, 1984.

 

16.       Creese, I., Sibley, D.R., and Leff, S.E., Agonist Interactions with Dopamine Receptors:  Focus on Radioligand Binding Studies, Federation Proceedings 43: 2779-2784, 1984.

 

17.       Sibley, D.R., Nambi, P. and Lefkowitz, R.J., Molecular Mechanisms of Hormone Receptor Desensitization, In Molecular Mechanisms of Transmembrane Signaling, Molecular Aspects of Cellular Regulation, (eds.) P. Cohen, M. Houslay, Vol. 4, pp. 359-374, 1985.

 

18.       Cerione, R.A., Benovic, J.L., Codina, J., Staniszewski, C., Sibley, D.R., Winslow, J., Gierschik, P., Somers, R., Strulovici, B., Spiegel, A.M., Neer, E.J., Birnbaumer, L., Lefkowitz, R.J., and Caron, M.G., Reconstitution of the b-Adrenergic-Coupled Adenylate Cyclase System into Phospholipid Vesicles, In Adrenergic Receptors, Molecular Properties and Therapeutic Implications, Symposia Medica Hoechst, (eds.) R.J. Lefkowitz, E. Lindenlaub, Vol. 19, pp 299-326, 1985.

 

19.       Nambi, P. Stadel, J.M., Sibley, D.R., Strulovici, B., Caron, M.G., and Lefkowitz, R.J., Mechanisms of b-Adrenergic Receptor Desensitization, In Adrenergic Receptors, Molecular Properties and Therapeutic Implications, Symposia Medica Hoechst, (eds.) R.J. Lefkowitz, E. Lindenlaub, Vol. 19, pp. 437-451, 1985.

 

*20.     Sibley D.R. and Lefkowitz, R.J., Molecular Mechanisms of Receptor Desensitization Using the b-Adrenergic Receptor-Coupled Adenylate Cyclase System as a Model, Nature 317: 124-129, 1985.

 

*Listed in the ISI Atlas of Science as a "Core Document" in the topic: "Regulation of b-

Adrenergic Receptors", 1987.

 

21.       Caron, M.G., Benovic, J.L., Leeb-Lundberg, L.M.F., Cerione, R.A., Regan, J.W., Lomasney, J.W., Cotecchia, S., Nakata, H., Sibley, D.R., Strasser, R.H., and Lefkowitz, R.J., Biochemical Characterization of the Adrenergic Receptors: Regulation of Responsiveness by Phosphorylation of the Receptors, In The Ninth International Symposium on Brain Sciences, (Y. Tsukata, ed.), Japan Scientific Societies Press, Tokyo, Japan, pp. 27-43, 1986.

 

22.       Caron, M.G., Benovic, J.L., Leeb-Lundberg, L.M.F., Cerione, R.A., Regan, J.W., Cotecchia, S, Lomasney, J., Nakata, H., Sibley, D.R., Strasser, R.H., Strulovici, B. and Lefkowitz, R.J., Biochemical Pharmacology of the Adrenergic Receptors:  Regulation of Responsiveness by Phosphorylation of the Receptors, In New Tests for New Drugs, (ed.) S. Garattini, Wichtig Editore, Milano, Italy, Vol. 3, pp 3-22, 1987.

 

23.       Sibley, D.R., Benovic, J.L., Caron, M.G. and Lefkowitz, R.J., Molecular Mechanisms of b-Adrenergic Receptor Desensitization, In Advances in Experimental Medicine and Biology, Vol. 221:  Molecular Mechanisms of Neuronal Responsiveness, (eds.) Y.H. Ehrlich, R.H. Lenox, E. Kornecki, W.O. Berry, Plenum Press, pp 253-276, 1987.

 

24.       Sibley, D.R., and Lefkowitz R.J., b-Adrenergic Receptor-Coupled Adenylate Cyclase:  Biochemical Mechanisms of Regulation, Molecular Neurobiology 1: 121-154, 1987.

 

*25.     Sibley, D.R., Benovic, J.L., Caron, M.G., and Lefkowitz, R.J., Regulation of Transmembrane Signaling by Receptor Phosphorylation, Cell 48: 913-922, 1987.

 

*Included among the top 100 Life-Sciences articles published in 1987 and cited in 1987

             and 1988, Current Contents, 17: 3-18, 1990.

 

26.       Sibley, D.R., Benovic, J.L., Caron, M.G., and Lefkowitz, R.J., Phosphorylation of Cell Surface Receptors: A Mechanism for Regulating Signal Transduction Pathways, Endocrine Reviews 9: 121-157, l988.

 

27.       Sibley, D.R. and Lefkowitz, R.J., Biochemical Mechanisms of b-Adrenergic Receptor Regulation, ISI Atlas of Science: Pharmacology 2: 66-70, l988.

 

28.       Sibley, D.R., Dopamine Receptors, Quarterly Review of Biology 63(3): 359, 1988.

 

29.       Sibley, D.R., Cloning of a D3 Subtype Expands the Dopamine Receptor Family, Trends in Pharmacological Sciences 12: 7-9, 1991.

 

*30.     Sibley, D.R. and Monsma, F.J., Jr., The Molecular Biology of Dopamine Receptors, Trends in Pharmacological Sciences 13: 61-69, 1992.

 

*Most highly cited TiPS article for 1992, Trends in Pharmacological Sciences 17 (4):

123, 1996.

 

31.       Sibley, D.R., Monsma, F.J., Jr., Gerfen, C.R., and Mahan, L.C., Molecular Cloning of D1 and D2 Dopamine Receptors, In Progress in Parkinson's Disease - 2, (eds.) F. Hefti and W.J. Weiner, Futura Publishing, pp. 201-214, 1992.

 

32.       Sibley, D.R., Monsma, F.J., Jr., and Shen, Y., Molecular Neurobiology of Dopaminergic Receptors, International Review of Neurobiology Vol. 35, pp. 391-415, 1993.

 

33.       Monsma, F.J., Jr. and Sibley, D.R., Molecular Cloning and Expression of a D1 Dopamine Receptor, In Methods in Neurosciences, Vol. 12: Receptors: Molecular Biology, Receptor Subclasses, Localization, and Ligand Design, (ed.) P.M. Conn, Academic Press, pp. 41-55, 1993.

 

34.       Sibley, D.R., Monsma, F.J., Jr., and Shen, Y., Molecular Neurobiology of D1 and D2 Dopamine Receptors, In, Neuroscience Perspectives, D-1:D-2 Dopamine Receptor Interactions:  Neuroscience and Psychopharmacology (eds.) P.G. Jenner and J.L. Waddington, Academic Press, pp. 1-21, 1993.

 

35.       Jose, P.A., Felder, R.A., Monsma, F.J., Jr., Sibley, D.R., and Mouradian, M.M., Molecular Biology of Dopamine Receptors: An Overview, In Cardiovascular and Renal Actions of Dopamine, (ed.) P. Soares-da-Silva, Pergamon Press, pp. 51-61, 1993.

 

36.       Sibley, D.R., Just the Facts, Trends in Pharmacological Sciences 15: 431-432, 1994.

 

37.       Ariano, M.A. and Sibley, D.R., Development of Anti-Receptor Antibodies Using Synthetic Peptides, In Methods in Neurosciences: Receptor Molecular Biology, (ed.) S. Sealfon, Academic Press, pp. 455-469, 1995.

 

38.       Sibley, D.R., Molecular Biology and Pharmacology of Dopamine Receptors, In Molecular and Cellular Mechanisms of Neostriatal Function, (eds.) M.A. Ariano and J. Surmeier, The R. G. Landes Co., pp. 255-272, 1995.

 

39.       Sleight, A.J., Boess, F.G., Bourson, A., Sibley, D.R., and Monsma, F.J., Jr., 5-HT6 and 5-HT7 Serotonin Receptors: Molecular Biology and Pharmacology, Neurotransmissions 11(3): 1-5, 1995.

 

40.       Sibley, D.R. and Neve, K.A., Regulation of Dopamine Receptor Function and Expression, In, The Dopamine Receptors, (eds.) K.A. Neve and R.L. Neve, Humana Press, pp. 383-424, 1996.

 

41.       Roth, B.L. and Sibley, D.R., Commentary on "Atypical Neuroleptics Have Low Affinity for Dopamine D2 Receptors or are Selective for D4” by Seeman et al., Neuropsychopharmacology 16: 114-115 1997.

 

42.       Sleight, A.J., Boess, F.G., Bourson, A., Sibley, D.R., and Monsma, F.J., Jr., 5-HT6 and 5-HT7 Receptors: Molecular Biology, Functional Correlates and Possible Therapeutic Indications, Drug News and Perspectives 10: 214-224, 1997.

 

43.       Waddington, J.L., Deveney, A.M., Clifford, J., Tighe, O., Croke, D.T., Sibley, D.R., and Drago, J., Behavioral Analysis of Multiple D1-like Dopamine Receptor Subtypes: New Agents and Studies in Transgenic Mice with D1A Receptor Knock-Out, In, "Catecholamines: Bridging Basic Science with Clinical Medicine," Advances in Pharmacology, Academic Press, Vol. 42, pp. 514-516, 1997.

 

44.       Sibley, D.R., Ventura, A.L.M., Jiang, D., and Mak, C., Regulation of the D1 Dopamine Receptor Through cAMP-Mediated Pathways, In, "Catecholamines: Bridging Basic Science with Clinical Medicine," Advances in Pharmacology, Academic Press, Vol. 42, pp. 447-450, 1997.

 

45.       Lachowicz, J.E. and Sibley, D.R., Molecular Characteristics of Mammalian Dopamine Receptors, Pharmacology & Toxicology 81: 105-113, 1997.

 

46.       Waddington, J.L., Deveney, A.M., Clifford, J., Tighe, O., Croke, D.T., Sibley, D.R., and Drago, J., D1-like Dopamine Receptors: Regulation of Psychomotor Behavior, D1-like:D2-like Interactions and Effects of D1A Targeted Gene Deletion, In, "Dopamine Receptor Subtypes: from Basic Science to Clinic, (Eds. P. Jenner and R. Demirdamas), IOS Press, Amsterdam, pp. 45-63, 1998.

 

47.       Sibley, D.R., New Insights into Dopaminergic Receptor Function Using Antisense and Genetically Altered Animals, Annual Review of Pharmacology and Toxicology 39: 313-341, 1999.

 

48.       Schetz, J.A. and Sibley, D.R., Metal Cations as Atomic Scale Probes of G-Protein Coupled Receptor Structure and Function, In "Structure/Function Analysis of G-Protein-Coupled Receptors" (ed.) J. Wess, Receptor Biochemistry and Methodology, Vol. 3, John Wiley & Sons, pp 121-140, 1999.

 

49.       Sibley, D.R., Gardner, B, Peters, J.D., and Kim, O.-J., Structural Insights into D1 Dopamine Receptor Phosphorylation and Desensitization, In “Catecholamine Research: From Molecular Insights to Clinical Medicine” (eds) T. Nagatsu, R. Nabeshima, R. McCarthy and D. Goldstein, Kluwer Academic/Plenum, pp. 159-162, 2002.

 

49.       Lachowicz, J.E. and Sibley, D.R., Dopaminergic Receptor Function Defined by Studying Genetically Altered Mice, In “Dopamine Receptors and Transporters” (eds.) A. Sidhu, M. Laruelle, P. Vernier, Marcel Dekker, Inc., pp. 295-320, 2003.

 

50.       Homes, A., Lachowicz, J.E. and Sibley, D.R., Dopamine Receptor Knockout Mice Reveal New Insights into Receptor Function and Pharmacology, Neuropharmacology 47/8: 1117-1134, 2004.

 

51.       Yang, Z., Sibley, D.R., and Jose, P.A., D5 Dopamine Receptor Knockout Mice and Hypertension, Journal of Receptors and Signal Transduction 24: 149-164, 2004.

 

52.       O’Sullivan, G.J., Clifford, J.J., Tomiyama, K., Koshikawa, N., Drago, J., Sibley, D.R., Croke, D.T., and Waddington, J.L., D1-like Dopamine Receptor-Mediated Function in Congenic Mouse Mutants with D1 versus D5 Receptor ‘Knockout’, Journal of Receptors and Signal Transduction, 24: 107-116, 2004.

 

53.       Altar, C.A., Branchek, T.A., and Sibley, D.R., Nervous System Disorders (Editorial), Drug Discovery Today: Therapeutic Strategies, 3(4): 411-412, 2006.

 

54.       Schetz, J.A. and Sibley, D.R., Dopaminergic Systems, In “The Handbook of Contemporary Neuropharmacology” (eds.) D.R. Sibley, I. Hanin, M.J. Kuhar, P. Skolnick, John Wiley & Sons, Volume 1, pp. 221-256, 2007.

 

55.       Free, R.B., Hazelwood, L.A., Namkung, Y., Rankin, M., Rex, E., and Sibley, D.R., Synaptic Transmission-Intracellular Signaling, In “The Handbook of Contemporary Neuropharmacology” (eds.) D.R. Sibley, I. Hanin, M.J. Kuhar, P. Skolnick, John Wiley & Sons, Volume 1, pp. 59-106, 2007.

 

56.       Free, R.B., Hazelwood, L.A., and Sibley, D.R., Identifying Novel Protein-Protein Interactions using Co-immunoprecipitation and Mass Spectroscopy, Current Protocols in Neuroscience, Chapter 5: Unit 5.28, 2009.

 

57.       Hazelwood, L.A, Free, R.B., and Sibley, D.R., Dopamine Receptor Interacting Proteins (DRIPs), In, The Dopamine Receptors (2nd edition), K.A. Neve (ed.), Humana Press, pp 219-254, 2009.

 

58.       Rankin, M.L., Hazelwood, L.A., Free, R.B., Namkung, Y., Rex, E.B., and Sibley, D.R., Molecular Pharmacology of Dopamine Receptors, In “The Dopamine Handbook” (eds.) A. Bjorklund, S. Sunnett, L. Iversen, S. Iversen), Oxford University Press, pp 63-87, 2009.

 

59.       Skinberb, M., Sibley, D.R., Javitch, J.A., and Abi-Dargham, A., Imaging the High Affinity State of the Dopamine D2 Receptor: fact or fiction, Biochemical Pharmacology, 83: 193-198, 2011.

 

60.       Newman, A.H., Blaylock, B.L., Nader, M.A., Bergman, J., Sibley, D.R., Skolnick, P., Medication Discovery for Addiction: Translating the Dopamine D3 Receptor Hypothesis, Biochemical Pharmacology, 84: 882-890, 2012.

 

61.       Xiao J., Free R.B., Barnaeva E., Conroy J., Doyle T., Bryant-Genevier M., Taylor M.K., Southall N., Hu X., Ferrer M., Titus S., Zheng W., Sibley D.R., Marugan J.J., Discovery, optimization, and characterization of a novel series of dopamine D2 versus D3 receptor selective antagonists, Probe Reports from the NIH Molecular Libraries Program [Internet]. Bethesda (MD): National Center for Biotechnology Information, 2013.

 

62.       Chun, L.S., Free, R.B., Sibley, D.R., Calcium and phospholipase C signaling through dopamine receptors, In “Dopamine Receptor Technologies” (ed.) Mario Tiberi, Springer Press, pp. 251-264, 2015.

 

63.       Moritz, A.E., Free, B., Weiner, W.S., Southall, N., Ferrer, M., Hu, X., Jain, P., Aube, J., Sibley, D.R., Frankowski, K., Identification of a novel D3 dopamine receptor-selective agonist with allosteric properties. Probe Reports from the NIH Molecular Libraries Program [Internet]. Bethesda (MD): National Center for Biotechnology Information, 2015.

 

64.       Goldstein, D.S. and Sibley, D.R., Irwin J. Kopin, Neuropsychopharmacology, 42: 2656, 2017.

 

65.       Moritz, A.E., Free, R.B., and Sibley, D.R., Advances and challenges in the search for D2 and D3 dopamine receptor-selective compounds, Cellular Signaling, 41: 75-81, 2018.

 

66.       Sibley, D.R., Hazelwood, L.A, Amara, S.G., 5-Hydroxytryptamine (Serotonin) and Dopamine, In, Goodman and Gilman’s The Pharmacological Basis of Therapeutics (13th edition), L.L. Brunton (ed.), McGraw Hill, Chapter 13, pp. 225-242, 2018.

 

67.       Free, R.B., Clark, J., Amara, S.G., and Sibley, D.R., Neurotransmission in the Central Nervous System, In, Goodman and Gilman’s The Pharmacological Basis of Therapeutics (13th edition), L.L. Brunton (ed.), McGraw Hill, Chapter 14, pp. 243-266, 2018.

 

68        Sibley, D.R., Happy birthday to Mike – 75 years young, Journal of Neuroscience Research, 97(12): 1744-1745, 2019.

 

69.       Sibley, D.R. and Shi, L., A new era of rationally designed antipsychotics, Nature, 555: 170-172, 2018.

 

70.       Sibley, D.R., Luderman, K.D., Free, R.B., and Shi, L., Novel cryro-EM structures of the D1 dopamine receptor unlock its therapeutic potential, Signal Transduction and Targeted Therapy, 6(1): 205, 2021.

 

71.       Nichols, C.D., Amara, S.G., Sibley, D.R., 5-Hydroxytryptamine (Serotonin) and Dopamine, In, Goodman and Gilman’s The Pharmacological Basis of Therapeutics (14th edition), L.L. Brunton (ed.), McGraw Hill, Chapter 15, in press, 2022.

 

72.       Free, R.B., Underhill, S., Amara, S.G., and Sibley, D.R., Neurotransmission in the Central Nervous System, In, Goodman and Gilman’s The Pharmacological Basis of Therapeutics (14th edition), L.L. Brunton (ed.), McGraw Hill, Chapter 16, in press, 2022.

 

Link to all publications in PubMed: https://pubmed.ncbi.nlm.nih.gov/?term=sibley+dr&sort=date

Link to all publications and patents in Google Scholar: https://scholar.google.com/scholar?start=0&q=%22sibley+dr%22&hl=en&as_sdt=20000007

 

Mega Menu Visual Content